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                                           ABSTRACT 
 
Title: Predictors of Morbidity and Health related quality of life in children with Spina bifida 
aperta  
Aim/ Objectives:  To assess in childen with spina bifida aperta, the quality of life, renal 
impairment, various morbidity factors and those on various management modalities for 
neurogenic bowel and bladder. 
Materials and methods: 68 children with spina bifida aperta were assessed. A history which 
included general data, bowel or bladder related accidents and the number of garments changes 
per day was taken.  A clinical examination enumerating the lesion, presence of co morbidities, 
anthropometry and neurological examination were performed. 
A urine microscopy, serum creatinine and ultrasound of the abdomen were done and if abnormal 
were followed by a MCU and CMG. DMSA was done in case of VUR. All children who were 5 
years or more were administered questionnaires to assess the quality of life.  The data was 
entered in Microsoft excel and analyzed using SPSS 16.  
 
Results and conclusion: 31% of children were found to have poor quality of life. 38.24% of 
children had evidence of renal changes as evidenced by dilated upper tracts and/ or scarring at 
the time of evaluation. Urinary incontinence was seen in 68.9% and faecal incontinence in 
61.29%.  38.09% of children were not ambulant and hydrocephalus was seen in 11.76%. 58.82% 
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of children were on CIC whereas 35.48% were on bowel washes. None of the children had 
mental retardation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
 TABLE OF CONTENTS 
 
 
1. Introduction………………………………………….01 
2. Aims and Objectives…………………………………02 
3. Review of Literature…………………………………04 
4. Materials and Methods………………………………17 
5. Results and analysis………………………………….19 
6. Discussion…………………………………………….48 
7. Conclusion……………………………………………54 
8. Bibliography………………………………………….57 
   9. Appendix…………………………………………….. 61                           
 
 
 
 
 
1 
 
  
INTRODUCTION 
Spina bifida is a congenital neural tube defect that results in incomplete closure of the spinal 
column. Children with spina bifida aperta which includes meningocoele, meningomyelocoele 
and lipomeningocoele suffer from various systemic problems. The most commonly involved 
systems are the genitourinary system, the gastrointestinal system, the musculoskeletal system 
and the central nervous system.  
Advances in neurosurgical, orthopaedic and urological management of these children have 
resulted in a better life expectancy and a better quality of life especially in the developed 
world. Key elements in the management of these children include early closure of the defect 
with institution of appropriate medical, surgical and supportive measures and lifelong follow 
up. 
Studies on the health related quality of life in children with spina bifida aperta especially from 
our country have been very few. Knowledge of their quality of life with respect to the general 
population, the various morbidity factors affecting them and the time of development of one of 
the most important cause of mortality namely renal impairment may go a long way in helping 
the clinicians and the care givers improve their quality of life.   
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AIMS AND OBJECTIVES 
 
AIM:  
To evaluate children with spina bifida aperta who presented to our hospital during 2003 to 
2013. 
 
OBJECTIVES:  
 1.  To evaluate the Quality of life (QoL) in school going children with Spina bifida aperta.  
 2.  To identify the proportion of children having renal impairment at the time of presentation. 
 3. To assess the proportion of children having the various morbidity factors namely 
   Urinary incontinence 
   Fecal incontinence 
   Mental retardation 
   Mobility problems 
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4. To assess the proportion of children requiring the various management modalities in 
neurogenic bowel and bladder namely 
  Clean intermittent catheterization with or without Mitrofanoff procedure  
  Double voiding 
  Bowel enemas 
  Malone’s antegrade continent enemas. 
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REVIEW OF LITERATURE 
History and Aetiopathogenesis: 
Spina bifida is a congenital anomaly of the central nervous system. There are mainly three 
types of spina bifida: spina bifida occulta, meningocoele and meningomyelocoele. 
Meningocoele and meningomyelocoele together are called spina bifida aperta. In spina bifida 
occulta there is a defect in one or more of the spinal vertebra without any sac. In meningocoele, 
which is least common variety, there is a sac which is formed by the membranes that covers 
the spinal cord namely the meninges and this sac protrudes through a defect in the vertebra. 
The content of the sac is only cerebrospinal fluid. In meningomyelocoele there is a sac formed 
by the meninges protruding through a defect in the vertebral column, with the contents of the 
sac being spinal cord, spinal nerve roots and cerebrospinal fluid.  
Historically spina bifida has been documented dating as far back as 1500 B.C.  However lack 
of further literature on the subject would suggest that the disease was considered hopeless and 
therefore insignificant.  The commonly used surgical methods at that time involved amputation 
of the neural sac and aspiration. The results were almost always fatal, due to CSF leak, 
meningitis and untreated hydrocephalus. Nicholas Tulp in 1641 and Fredrick Ruysch in 1691 
were among the first to conduct extensive case studies on spina bifida. These studies included 
an accurate physical description of the disorder, while stating that the condition was 
completely untreatable. 
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However better understanding of the pathophysiology of the disease and improved surgical 
techniques by the late nineteen and the early twentieth century resulted in improved rates of 
mortality and morbidity. Excision of the sac with primary skin closure was introduced by 
Lister while the use of musculo-facial flaps for closure of the defect was introduced by Bayer 
(1).  
The world wide incidence of spina bifida is about 1-3 per 1000 births (2) while the incidence in 
India is about 3.9-8.8 per 1000 birth (3). The world wide prevalence of the disease has been on 
the decline mainly because of better antenatal care, better nutrition and timely folic acid 
supplementation (4). 
The exact reason for the occurrence of spina bifida has not been found out yet but genetic and 
environmental factors including maternal diabetes, obesity, antiepileptic drugs like valproate, 
phenytoin, antimalarial drugs, folate antagonists like aminopterin, alcohol, mitomycin C and 
hypervitaminosis A  are said to play a role (5),(6).  Abnormalities in the homeobox gene have 
been recently implicated as a causative factor in the development of neural tube defects. It can 
occur either sporadically or in association with other congenital anomalies. 
Embryology 
The process of formation of the brain and spinal cord is called neurulation. Embryogenesis in 
the first 2 months of gestation can be divided into 23 stages. Neural plate is formed in the 8th 
stage at around the 18th day. This is followed by formation of the neural folds and their 
subsequent fusion. The caudal expansion of the neural tube and its subsequent closure is 
completed by day 25. The most caudal portion of the spinal cord is formed by a process of 
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secondary neurulation. Spina bifida aperta is a defect in the primary neurulation where the 
caudal region of the neural tube fails to fuse (7). Defect in secondary neurulation causes occult 
spinal dysraphism. 
Pathophysiology and Management 
Spina bifida aperta can occur anywhere in the back from the cervical to the sacral region with 
the lumbo-sacral area being the most commonly affected.  The immediate management of 
spina bifida aperta is to repair and close the lesion in the back. It is either done as an 
emergency in a ruptured variety with CSF leak or electively in the non ruptured type. The 
extent of neurological dysfunction cannot be predicted by the clinical appearance of the lesion. 
The organs usually involved are the kidney and urinary bladder, the bowel and the lower limbs. 
The neurological dysfunction that affects the various systems is the reason for the major 
morbidity and mortality seen in a case of spina bifida aperta. 
The neurological dysfunction that occurs in spina bifida aperta can either be congenital/ early 
or late. In the first category the child will be born with the neurological deficits due to 
defective spinal nerves. The most common cause for late deterioration is tethering of the spinal 
cord. Tethering of the spinal cord can manifest as deterioration in motor power or gait, pain, 
altered sensation, changes in bladder function, and new onset of deformity in the legs and 
spine. Here the spinal cord is held in the original position and is prevented from ascending 
within the thecal sac during growth of the individual. The causes implicated for the 
neurological dysfunction are: 1. Sustained traction on the cord with growth of the bony spine 
leads to stretching of the cord and neuronal disruption. 2. Ischemia of the cord. 3. Repeated 
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hyper flexion of the spine like during  sports activities causes acute neuronal injury at the site 
of tethering (8). 
As this is a dynamic problem it cannot be identified with static investigations like MRI and CT. 
If tethering is the cause for neurological deterioration then treatment should be aimed at 
removal of the tissue causing tethering and thereby releasing the cord.  
Neurological dysfunction can result in abnormalities of the genitourinary system, the 
gastrointestinal system, the musculoskeletal system and the central nervous system. The 
various system anomalies are discussed below.  
Genitourinary system: Micturition is a spinal reflex modulated by the central nervous system. 
The bladder and the urethra are innervated by three sets of peripheral nerves arising from the 
autonomic nervous system and the somatic nerves. Under normal conditions the detrusor, 
bladder neck and the external sphincter act in synergy to store urine and evacuate it completely 
at an appropriate time. The changes in the storage pressure of bladder between it being empty 
and full is less than 10-15 cm of water. This property of the bladder is known as 
accommodation. The normal voiding pressure ranges from 50-80 cm of water for a male and 
40-65 cm of water for a female. When the filling pressure exceeds 40 cm of water, it leads to 
reduced glomerular filtration, decrease ureteral drainage, obstructive hydronephrosis and 
vesico ureteric reflux. 
 Majority of children with spina bifida aperta are known to have neurogenic bladders. The 
reason being disordered innervation of the detrusor and the external sphincter resulting in 
detrusor- sphincter dyssynergia (9). Here reflex relaxation of the external sphincter that occurs 
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when the detrusor contracts is lost. This initially causes detrusor hyperreflexia where there is 
intermittent elevation in the filling pressure to more than 40 cm of water (10). Persistence of 
dyssynergia results in muscular hypertonia with collagen deposition causing persistent 
elevation of filling pressure, or detrusor decompensation which is also known as myogenic 
failure. In some children, the bladder may function reasonably well, but the urinary sphincter 
may be weak, sometimes called intrinsic sphincter dysfunction.  These children are not able to 
hold urine and may leak even when their bladder is not reached full capacity. 
At one end of the spectrum is a hyperactive poorly compliant bladder (muscular hypertonia) 
which tends to be small, and does not hold urine well resulting in urinary incontinence.  The 
bladder pressures are very high leading to back-pressure changes to the kidneys resulting in 
hydronephrosis or hydroureteronephrosis and renal damage if left unchecked over a long 
period of time. At the other end of the spectrum, there is a hypotonic neurogenic bladder 
(myogenic failure). In these children, the bladder is large and lax albeit with improper 
emptying. These children tend to have a full bladder all of the time and may be prone to 
urinary tract infections. In addition, if the bladder gets too full, they may have overflow 
incontinence. 
The classification of neurogenic bladder has been given by the Urology section of the 
American Academy of Paediatrics in conjunction with the Urodynamic Society’s classification, 
the International Continence Society and most recently the International Children’s Continence 
Society (11).  
The classification is based on dysfunction of a specific area rather than aetiology. 
1.  Storage: Based on detrusor tone and urethral closing mechanism.  
9 
 
Detrusor tone can be normal or increased as in cases of non-elastic, hyperreflexic bladder.   
Urethral closing mechanism is based on competence of the bladder neck and the external 
sphincter. Incompetence can result in non reciprocal activity or periodic hypoactivity.   
2. Evacuation: is based on detrusor contraction and urethral closing mechanism. 
            Detrusor contraction can be normal or underactive (areflexic or hypoactive).  
Defects in urethral closing mechanism can be due to non synchronous action between the 
bladder neck and the external sphincter.  
The major goal to be attained in managing a neurogenic bladder is to make the bladder a low, 
safe pressure zone inorder to protect the kidneys from urinary tract infections and back 
pressure changes.  Other goals are prevention of urinary incontinence, and management of any 
associated vesicoureteric reflux (12). A complete assessment and individualized management 
is required for these children. In addition, neurogenic bladders can change over time. Thus 
these children need to be on follow up their entire life.  Investigations like serum creatinine and 
ultrasound abdomen helps in quantifying the degree of renal impairment. Ultrasound also helps 
in assessing the bladder thickness and presence of a significant post void residue. A 
Micturating Cystourethrogram (MCU) helps in identifying vesico ureteric reflux, bladder 
capacity and evaluating the anatomy of the bladder and bladder neck. A DMSA is useful in 
identifying renal scars in the setting of reflux and a cystometrogram (CMG) helps in 
determining the type of bladder and sphincter problem. 
The mainstay of treatment in these children is early characterization and institution of proactive 
therapy.  Clean Intermittent Catheterization (CIC) (13) in combination with anticholinergics is 
the standard therapy for children with neurogenic bladder (14). CIC was a landmark 
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intervention in Pediatric Urology and was first described by Lapides (15) at the University of 
Michigan. CIC involves passing a small, soft catheter through the urethra into the bladder to 
empty the bladder in order to prevent infections and incontinence. Catheters are made of a soft 
silastic plastic material to prevent exposure to latex and development of latex allergies (16). 
Lately, newer catheters with hydrophilic coatings have been introduced which makes it very 
slippery and allows it to pass through the urethra without much friction or discomfort.  Most of 
the urinary tract infections in children with neurogenic bladders are caused by urinary stasis 
and if the urine is emptied completely, this will help prevent infection. Thus, although it seem 
counter-intuitive, the best treatment to prevent infections and incontinence in children with 
neurogenic bladders is to empty the bladder with CIC. To further protect against infections, 
some catheters are impregnated with antibiotic coatings as well. If catheterization through the 
urethra is difficult, alternative catheterizable channels using the appendix which is known as 
Mitrofanoff and bowel which is known as Monti tube have been described. CIC also allows 
bladder emptying before the occurrence of an otherwise spontaneous ‘high pressure voiding’ 
which is detrimental for the kidneys. 
Anticholinergic medications like oxybutynin is a bladder smooth muscle relaxant. It is a M3 
selective receptor antagonist with antispasmodic, local anaesthetic and calcium channel 
blocking action (17).  It helps in improving the bladder dynamics by suppressing hyperreflexia 
and hypertonia causing reduction of high pressure bladder storage and high pressure emptying 
with increase in capacity of the neurogenic bladder (18). The action of these medications is 
mainly confined to the detrusor with little effect on the sphincter. The usual oral dose is 0.3-0.6 
mg/kg/day in three divided doses.  
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In children with ineffective response to oral oxybutynin, intravesical instillation of the same 
drug has been found to be highly efficacious (19),(20). It was found that more potent and 
longer duration of action of intravesical oxybutynin was due to reduced first pass metabolism 
(21) and due to a direct local effect on the detrusor on intravesical instillation. Intravesical 
oxybutynin can be administered upto 0.9 mg/kg/day. Newer anticholinergic like tolterodine is 
given in those who are not tolerating oxybutynin. Intravesical instillation of botulinum toxin A 
and and resiniferatoxin (22) can be given to patients not responding to anticholinergics.  In the 
case of a lax sphincter,  sympathomimetics are given to increase the tone of the sphincter (23).  
Though CIC and drugs are effective in many cases some children will continue to have or may 
later develop high pressure poorly compliant bladders. These children are at a risk for renal 
damage. In such cases, surgery to enlarge the bladder with simultaneous decrease in bladder 
pressure may be considered. This is called bladder augmentation (24) and uses a piece of 
hollow viscous mostly from the gastro intestinal tract to augment, or enlarge, the bladder. This 
is a very effective procedure to reduce the bladder pressures and prevent upper tract changes. 
The only downside of this procedure is that lifelong washes and medication is needed and there 
is a small risk of malignancy (25). If necessary, procedures to correct vesicoureteric reflux and 
narrow the bladder neck may also be performed along with augmentation. There are various 
forms of bladder neck reconstruction which help in increasing the bladder outlet resistance to 
correct urinary incontinence. 
 
Gastrointestinal tract:  Normal bowel function depends on the rectal sensation, patency of the 
sphincter complex and effective peristalsis. Children with spina bifida aperta often have 
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neurogenic dysfunction of the bowel resulting in constipation or fecal incontinence (26). While 
bowel accidents often seem like diarrhea, it is of a spurious nature as most of the bowel 
contents are well formed. Fecal continence has been proven to have a considerable impact on 
social life (27). Management of neurogenic bowel involves a patient oriented program. For 
mobile patients rectal enemas with normal saline and a mild irritant like glycerine are useful.  
In patients who are not mobile and in those with severe incontinence which is not controlled 
with rectal enemas, an Ante grade Continent Enema (ACE) using the existing appendix or a 
newly created conduit that acts as a catheterizable channel to gain access to the colon has been 
described by Malone (MACE) (28). Low profile caecostomy tubes with stopper buttons called 
trap door Chait catheters (29) which can be introduced percutaneously or laparoscopically (18) 
are also in vogue. 
 
Musculoskeletal problems: There are various orthopedic problems associated with MMC. 
Deformities follow three patterns: 1. prenatal uterine pressure on paralyzed limbs; 2. postnatal 
causes which are either postural or secondary to muscular imbalance and 3.defective 
innervation of the muscles leading to atrophy of the legs. As paralysis happens in the fetus, 
orthopedic problems like clubfoot, arthrogryposis of the legs and developmental dysplasia of 
hip is usually seen at birth. Kyphosis is sometimes present and can hinder surgical closure 
thereby preventing the child from lying supine. Scoliosis (30) may develop later and is more 
common among children with higher lesions (i.e. above L3). Other associated anomalies are 
congenital fusion of the vertebra, congenital lumbo sacral spondylolisthesis, hypoplasia of the 
sacrum and abnormal ribs (31). 
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Another important factor to be considered is the absence of sensation in the lower extremities 
resulting in the formation of pressure sore. There can be spastic or flaccid paralysis depending 
on the level of lesion. Prognosis varies by the level of cord involvement and the number and 
severity of associated anomalies. Prognosis is worse for children with higher cord level (e.g. 
thoracic) lesions or who have kyphosis and other associated congenital anomalies. With 
correction of the orthopaedic anomaly and proper conservative care, most children do well.  
 
Central nervous system anomalies: The most common CNS anomaly seen in patients with 
spina bifida aperta is hydrocephalus. The incidence of hydrocephalus in these children are said 
to be around 80% (32) according to Western literature. The reason for hydrocephalus has been 
postulated to be due to aqueduct stenosis (33) and Arnold Chiari malformation type 2 (34). 
When significant hydrocephalus occurs, white matter fibers such as the corpus callosum are 
often stretched resulting in abnormal spatial and motor skills. It also causes selective thinning 
of posterior brain regions which are associated with the development of spatial skills.   
 
In type 2 Chiari malformation, there is
 
cerebellar hypoplasia with caudal displacement of the 
hindbrain through the foramen magnum. This obstructs the outflow of cerebrospinal fluid 
(CSF) from the fourth ventricle. The end result is progressive hydrocephalus which may be 
diverted through a ventriculo-peritoneal shunt. The cerebellum is responsible for fine motor 
functions and is also a gateway for a variety of skills that involve attention, planning, and 
learning.  
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There are various defects associated with Arnold- Chiari malformation which are: 
-Cranial Nerve Palsies and visual deficits due to the enlarged ventricles compressing on the 
adjacent brain structures 
-Cognitive and perceptual problems namely lower intellect, memory deficits and distractibility 
-Cocktail party personality which is chattering speech with limited content and visual 
perceptual deficits. 
-Motor dysfunction in the form of in-coordinated halting and deliberate movements instead of 
smooth and continuous. 
-Spasticity due to upper motor neuron type lesion (35).  
It is a lesser known fact that many children with spina bifida aperta have other congenital brain 
anomalies like partial agenesis of the corpus callosum. Since the corpus callosum is the major 
fiber pathway connecting the two cerebral hemispheres, agenesis results in reduced 
communication between the two cerebral hemispheres causing abnormalities in spatial and 
motor skills. Despite the extent to which the central nervous system is altered, few children are 
mentally deficient though some are simply characterized as slow learners. 
 
Children with spina bifida aperta have a particular type of learning disability called a "non-
verbal" learning disability. Non-verbal learning disability is characterized by problems with 
mathematics and writing while reading and comprehension is fairly well preserved. In 
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particular, word recognition and spelling skills are often well developed. This is also associated 
with social problems, particularly when the child enters adolescence. As adolescents, some 
children with spina bifida aperta may become more lethargic and somewhat depressive, 
showing tendencies towards social isolation. 
 
Many children with spina bifida aperta have difficulties with memory and attention. These 
problems are not well understood, but often manifests as difficulties with attention span, 
attention shifting, and controlling the focus of attention. This reflects a reduction in the level of 
arousal and alertness and is different from the attention problem seen in Attention Deficit 
Hyperactivity disorder (ADHD) children.  The attention problems that characterize many 
children with spina bifida aperta tend to be under detected and under treated. These behaviors, 
along with the manifestations of reduced arousal are often interpreted as passivity, lack of 
interest in learning, and poor motivation by many individuals in school settings (36).  
 
 Other problems: Development of latex allergy is another factor that needs to be considered in 
these children (37). Latex is found in a lot of materials including red rubber catheters, medical 
gloves and medical equipment. These children may come in contact with latex while 
performing clean intermittent catheterization and during surgical interventions. Thus they are 
at a high risk of developing latex allergies which can be quite severe and life threatening. 
Therefore, attempts to avoid latex exposure and sensitization are warranted to help protect 
against latex allergies 
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Importance of folic acid in prevention (38),(39) of spina bifida has to be emphasized strongly 
mainly with health education . Folic acid is required for normal neural tube formation and has a 
protective effect against the development of spina bifida. Folic acid is supplemented as a 
dietary or vitamin supplement at 400 micrograms per day to women of child bearing age 
commencing three months prior to conception (40). 
 
While meningitis is a common cause of death in an infant with spina bifida, renal failure and 
ventricular shunt complications are the usual causes of death in older children. For this reason 
after initiation of appropriate treatment for the various problems, a lifelong follow up is 
mandatory.  Studies on the health related quality of life in children with meningomyelocele 
especially from our country have been very few. Knowledge of their quality of life with respect 
to the general population, various morbidity factors affecting them and the time of 
development of one of the most important cause of mortality viz. renal impairment may go a 
long way in helping the clinicians and the care givers improve their quality of life.   
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MATERIALS AND METHODS 
The purpose of this study was to evaluate children with spina bifida aperta who were treated in 
the Departments of Paediatrics and Paediatric Surgery during 2003 to 2013. Patient details 
were obtained from the operation notes and the IP records maintained in the department.  
Patients 
 A total of 68 patients with spina bifida aperta who came for follow up were evaluated. They 
were further divided into two categories- five years or more and less than five years.  
Inclusion criteria 
All patients with a diagnosis of meningocoele, lipomeningocoele and meningomyelocele who 
were treated in the Department of Paediatrics and Paediatric Surgery between the years 2003 – 
2013 were included in the study. 
Exclusion criteria 
All cases of spina bifida occulta were excluded. 
Methodology 
All children with spina bifida aperta who followed up in Paediatric surgery following the 
intimation were evaluated. The children were further divided into two groups: one that was five 
years or more and the other which was less than five years. In all children a history which 
included age, gender, date of birth, place and type of delivery and gestational age at the time of 
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delivery, any bowel or bladder related accidents and the number of changes of garments per 
day was taken.  Further a clinical examination which included enumerating the type of lesion, 
the vertebral levels involved, presence of co morbidities, anthropometry, motor power at the 
hip, knee and ankle, contractures if any, sensory level, saddle anesthesia, presence of sores, 
reflexes like anal wink and bulbocavernosus, bladder sensation if present, whether the bladder 
is palpable or expressible and the presence of rectal sensation was assessed   
Laboratory investigations like urine microscopy, serum creatinine and an ultrasound of the 
abdomen was done initially. If these preliminary investigations showed any abnormality a 
MCU and CMG (optional- was not done in infants) was done. If the MCU revealed a VUR 
then a DMSA scan was done. 
In children who were 5 or more, a quality of life assessment was also done along with the 
above mentioned assessment. Four instruments namely Barthel activities of daily living index, 
PIN-Q for paediatric urinary incontinence quality of life, Visual analogue score for general 
quality of life and a patient generated index was administered and the quality of life with 
respect to disability was assessed. 
The data was entered in Microsoft excel and analysis done using SPSS. Descriptive statistics 
were reported using mean with or without standard deviation and median with IQR. 
Continuous variables were reported with ‘n’ and ‘%’ was used for categorical variables. 
Relation between the three quality of life instruments was assessed by Pearson’s correlation. 
Simple linear regression was used to quantify the relation and Chi square test was used to find 
the association between the three instruments. 
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RESULTS AND ANALYSIS 
A total of 68 children were assessed. They were divided into two groups. The first group 
comprised of children who were 5 years or more. The second group comprised of children who 
were less than 5 years, 19 of whom were infants. The male female distribution of each group is 
summarized below.   
 
 
Fig 1:  Distribution According to age and Gender 
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The patients were classified depending on whether the primary lesion was a 
meningomyelocoele (MMC), a meningocoele (MC) or a lipomeningocoele (LMC) 
(Illustration.1, 2, 3). The results are summarized below in fig.2.  
 
 
Fig. 2: Distribution of Patients (MMC- Meningomyelocoele, MC- Meningocoele, LMC- 
Lipomeningocoele) 
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Fig. 3: Percentage distribution of 
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The various morbidity factors affecting children more than 5 years were grouped into three 
categories. They were incontinence (bowel and bladder), mobility problems and central 
nervous system problems. A total of 22 
and 5 had CNS problems. The 
Fig. 4: Morbidity factors depicted in a V
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Fig. 5: Incontinence issues  
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Genitourinary system: 
Urological evaluation was done in all 68 children. Back pressure changes as evidenced by 
hydronephrosis on an ultrasound or the presence of renal scars on a DMSA scintigraphy were 
documented.  All 68 children underwent an ultrasound abdomen whereas 28 had a MCU and 
17 had a DMSA scan none of whom were infants. 
 26 of the 68 children showed hydronephrosis on an ultrasound. Of these 26 children 21 had a 
MCU and 14 of them had a VUR and 8 of them were bilateral. 17 children had a DMSA scan 
and scars were seen in 5 of them. It was seen that 65.5% of children who were five years or 
more had upper tract dilatation and 17.95% of children who were less than five years had the 
same.  
Renal involvement No. of patients Percentage 
‹ 5 years   7 (n= 39) 17.95% 
 ≥ 5 years  19 (n= 29) 65.50% 
Table 2: Children with upper tract dilatation 
 
Even though 65.5% of children who were five years or more had upper tract dilatation, the 
time at which they developed these changes would have been different. Keeping this in mind, 
the time at which each of the 26 children developed upper tract dilatation was obtained from 
the records. It was seen that 19 of the 26 children (73.07%) developed upper tract dilatation by 
the time they were five years old. There were 19 children who were infants at the time of 
evaluation and 4 of them [21.05%] had upper tract dilatation. 
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Fig. 6: Age wise proportion of children with upper tract dilatation. 
 
Looking at presence of upper tract dilatation as the event of interest, an attempt was made to 
calculate the age at onset of developing upper tract changes. An ‘Ogive’ was plotted with the x 
axis showing the age in years at the time of development of upper tract dilatation and the y axis 
showing the proportion of children in each age group in our cohort that developed upper tract 
dilatation. The time at which the largest proportion of children developed these changes was at 
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5-6 years. Across the age groups the proportion of children developing upper tract dilatation 
seems to be uniform and ranges from 30-38%. 
Very high bladder pressure is considered as the most important causative factor for upper tract 
deterioration and therapeutic measures are directed towards reducing bladder pressures. 42 of 
the total 68 children were either put on drugs or CIC or underwent diversion procedures or 
augmentation of the bladder (Illustration.8) to offset the upper tract changes that resulted from 
high bladder pressures. 26 children underwent clean intermittent catheterization (CIC) alone 
(Illustration.9), 20 children were put on bladder relaxing drugs like oxybutynin and 
amitriptyline, 16 children underwent bladder augmentation with CIC and 2 children underwent 
other diversion procedures like vesicostomy and ureterostomy.  
Procedures ‹ 5 years (n= 39) ≥ 5 years (n= 29)  
Bladder augmentation 
with CIC     * 1 13 
Vesicostomy 0 1 
Ureterostomy 1 0 
CIC alone  + 13  13 
Drugs with CIC 4 16 
Table 3: Modes of bladder management    
           (*1 patient practicing urethral CIC; + 1 patient uses Mitrofanoff.)  
 
Of the 14 children who had a bladder augmentation, an appendicular Mitrofanoff (Illustr.8) 
was used for bladder catheterization in 13 children while the urethra was used for bladder 
catheterization in 1 child.  Of the 26 children who were put on CIC without augmentation, the 
urethra was used for catheterization in 25 while in one a Mitrofanoff was used.  
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28 children were not on CIC of which 14 were infants. 3 of these children inclusive of an infant 
had evidence of upper tract dilatation. 
 
Gastrointestinal system: 
A child is supposed to be potty trained by four years of age. The total number of children in 
this study who were more than four years old was 31. 12 children were continent to stools with 
3 of them being on daily washes. 11 children had occasional soiling with 6 of them being on 
daily washes. 8 children had severe incontinence that interfered with activities of daily living 
and only 2 of them were on daily washes.  
 
Musculoskeletal system:  
Musculoskeletal problems like immobility, pressure sores and contractures were seen in 27 out 
of a total of 42 patients who were more than 2 years old (64.28%).  
Mobility issues 
2 to ‹ 5 years  
(n= 13)  ≥ 5 years  (n=29) 
Not ambulant 9 7 
Ambulant with AFO  0 2 
Pressure sore 2 12 
Contractures 1 5 
Table 4:  Locomotor problems 
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The sensory levels were tested in all 68 children. Touch and temperature sensation was 
checked in children who were more than 3 years old whereas pain was tested in children who 
were less than 3 year.  It was seen that 73.53% of children had sensory deficits and 17.64% had 
pressure sores (Illustr.7). The results are summarized below.  
Levels of sensation No. of patients (n=68) 
Fully sensate 18 
L1 L2 15 
L3 L4 12 
L5 S1 23 
Table 5: Levels of sensation 
 
Central nervous system anomalies: 
A total of 8 patients (11.76%), 5 in children who were five or more and 3 in children less than 
five years, were found to have symptomatic hydrocephalus which required shunting. 7 patients 
underwent a ventriculo-peritoneal shunt while one patient had endoscopic third 
ventriculostomy after a failed VP shunt.  
Hydrocephalus No. of patients Percentage 
‹ 5 years 3 7.69% 
≥ 5 years 5 17.24% 
  Table 6: Children with hydrocephalus. 
 Associated anomalies:  
Other associated anomalies were found in 20 of the 68 
 
 
Fig. 7: Associated anomalies  
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Bony anomalies were seen in 18 patients (26.47%) and included developmental dysplasia of 
the hip (DDH), congenital talipes equino varus (CTEV), spinal anomalies like butterfly 
vertebra, partial sacral agenesis, fibular hemimelia and arthrogryphosis of the lower limb. 
(Illustration. 4, 5) 
Bony anomalies No. of patients 
DDH 11 
CTEV 10 
Butterfly vertebra 2 
Sacral agenesis 1 
Arthrogryposis 1 
Fibular hemimelia 1 
Table 7 : Bony anomalies 
 
Urological anomalies were seen in 5 patients and it included  
Undescended testis in 2 patients 
Solitary kidney in 1 patient 
Crossed fused ectopic kidney in 1 patient 
Hypospadias in 1 patient 
Gastrointestinal anomaly seen in 1 patient was a high anorectal malformation. 
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Quality of life (QoL) measures: 
The main contributors to the quality of life construct in children with spina bifida are thought 
to be incontinence, difficulty in ambulation and its resultant consequences. Since otherwise 
normal children become proficient in these domains by three to four years, the quality of life 
study was focused on children who were 5 years or more.  
Quality of life in 29 children who were 5 years or more was assessed by sequentially 
administering the Barthel activities of daily living index; the PIN-Q for urinary incontinence 
related quality of life measure and a visual analogue score for general quality of life.  
The Barthel activities of daily living index are a ten point assessment score with regards to 
activities of daily living. Scores of this index range from 0 to 20, with the best possible score 
being 20.  
PIN-Q also called the paediatric incontinence quality of life score measures the quality of life 
with regards to urinary incontinence. There are 20 questions each having a score from 0 to 4. 
The maximum score is 80 and the minimum score is 0, with 0 being the best possible score. 
Visual analogue scale measures the general quality of life with 0 being the least score and 100 
being the best and the maximum possible score. This is the most easily administered, 
comprehended and validated global measure of quality of life.  
A ‘patient generated index’ which was an open ended questionnaire was administered along 
with the above mentioned scales to measure the quality of life. Its purpose was to elicit issues 
affecting the quality of life that the patients’ care taker felt to be of importance and hitherto had 
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not been elicited. However there were difficulties in comprehending this instrument and 
therefore did not elicit an adequate response.  
 The values obtained were analyzed to see whether there was a significant association between 
the three instruments. The values were plotted in a scatter diagram and the significance was 
tested using the Pearson correlation coefficient. 
  BARTHEL 
INDEX PINQ VAS 
BARTHEL 
INDEX 
Pearson Correlation 1 -.171 .646** 
Sig. (2-tailed)  .376 .000 
N 29 29 29 
PINQ Pearson Correlation -.171 1 -.564** 
Sig. (2-tailed) .376  .001 
N 29 29 29 
VAS Pearson Correlation .646** -.564** 1 
Sig. (2-tailed) .000 .001  
N 29 29 29 
 Table 8  :**. Correlation is significant at the 0.01 level (2-tailed). 
 
   Fig. 8: PIN-Q V/s Barthel 
   Fig. 9: Barthel V/s Visual analogue score
Fig. 10: PIN-Q V/s Visual analogue score
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It was found that there was a statistically significant correlation for PIN-Q with visual analogue 
score and for Barthel index with visual analogue score. However a statistically significant 
correlation could not be obtained in PIN-Q with Barthel index, the reason probably being the 
lesser number of cases and the fact that Barthel evaluates more parameters, most of which do 
not relate to incontinence.  
A prediction equation was also obtained between PINQ and visual analogue score 
                                       PINQ = 84.15-0.51(VAS)  
                                                             
 
 
The median and the quartiles values were calculated from the scores of PIN-Q, Barthels and 
Visual analogue score.  The median and the quartile values for each of the indices are listed in 
table 9. 
 
  
VAS BI Total 
PINQ 
Total 
N Valid 29 29 29 
Missing 0 0 0 
Percentile
s 
25 50.00 11.0000 30.0000 
50 70.00 17.0000 45.0000 
75 82.50 18.5000 57.0000 
  Table 9: Quartile values for each of the indices 
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The number of children in each quartile was then calculated for all the indices. It was presumed 
that the children whose scores were below the median value will have a poor quality of life. 
The median value for Visual analogue score was 70 out of a maximum of 100, Barthel was 17 
out of 20 and PIN-Q score was 45 out of 80. The children whose scores were within the 25th 
centile were presumed to have an extremely poor quality of life, while those above the 75th 
centile were presumed to have a good quality of life.  
According to the Barthel index and PIN-Q 8 of the 29 children (27.6%) were having an 
extremely poor quality of life while according to the Visual analogue score 10 of the 29 
(34.5%) had the same. The children who had poor quality of life were seen to correlate across 
all quality of life instruments.  
The quality of life scores were calculated in children who were 5 or more and having different 
co-morbidities. An attempt was made to see whether there was a change in the quality of life 
scores with increasing number of co-morbidities. The results obtained were not statistically 
significant.  
Further an attempt was made to see whether there was a statistically significant correlation 
between PIN-Q and renal changes and whether higher score of PIN-Q corresponded with more 
renal changes. No statistically significant association was found between the two.  
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ILLUSTRATIONS 
 
 
Illustration.1: Closed meningomyelocoele 
 
Illustration.2: Open meningomyelocoele 
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Illustration.3: Meningomyelocele with patulous anal opening 
 
 
Illustration.4: CTEV in a child with Meningomyelocoele 
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Illustration.5: CTEV and DDH in a child with spina bifida aperta 
 
 
Illustration.6: Post operative scar of MMC repair. 
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Illustration.7:  Pressure sore 
 
 
Illustration.8: Bladder augmentation using large intestine and appendix mobilized for Mitrofanoff. 
 Illustration.9: CIC through the Mitrofanoff
Case 1 
8 year old boy presented with incontinence
Illustration.10: Ultrasound showing right hydro
40 
 
. 
nephrosis  
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Illustration.11: Ultrasound showing left hydronephrosis 
 
 
Illustration.12: Ultrasound showing irregular baldder with dilated terminal ureters 
 Illustration.13: MCU showing trabeculated bladder with open bladder neck
 
   
Illustration.14: CMG showing high pressure poorly compliant bladder
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 and left VUR.
. 
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The child underwent bladder augmentation with left ureteric reimplant and Mitrofanoff 
 
Illustration.15:  Post augmentation ultrasound shows partial resolution of right hydroureteronephrosis. 
 
Illustration.16: Post augmentation ultrasound shows partial resolution of left hydroureteronephrosis. 
 Illustration.17: MCU showing augmented bladder with resolution of VUR 
 
   
Illustration.18: Post operative CMG showing a compliant bladder.
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Case 2:  
A 13 year old girl who was not on CIC presented with UTI. 
.  
 Illustration.19: USG showed bilateral hydronephrosis. 
 
   Illustration.20:  MCU showing a trabeculated bladder with open bladder neck and no VUR. 
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   Illustration.21: CMG showed a high pressure poorly compliant bladder. 
She was put on Oxybutynin with three hourly CIC and night drainage. She was told to review 
after 6 months and plan for augmentation if there was no improvement. Repeat USG showed 
resolution of hydronephrosis. 
 
Illustration.22: Resolution of right hydronephrosis  
 Illustration.23: Resolution of left hydronephrosis
     Illustration.24: Post CIC cystometrogram
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 showed a compliant bladder 
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DISCUSSION 
 The outlook of spina bifida aperta has undergone a sea change over the past few decades. This 
condition had such poor prognosis in the 1960’s that people refused to operate on such babies. 
However better understanding of this congenital condition, its complications along with 
improvement in medical and surgical techniques have resulted in successful management of 
this condition by a multi disciplinary approach.  This change has been reflected in the 
improved survival rates of children with spina bifida aperta which has increased from 10% in 
the 1960’s to about 85% at present (41). 
General consideration: In our study, a total of 68 children with spina bifida aperta were 
evaluated. In this cohort, we encountered 19 infants during the period of study amounting to a 
calendar year. The children were further divided into two groups depending on whether their 
age was five years or more, or less than five years. 
 In our study, 43 of the 68 children were male [63.24%]. Mitchell et al in his study had 
observed that the incidence of spina bifida was higher in girls in the newborn period (7). 
Chopra et al gave a male female ratio of 1 to 1.3 (42).  
The most common lesion in our study was a meningomyelocoele (88.23%) as it was in 
literature.  The most common site of involvement of spina bifida aperta as per literature is the 
lumbar and sacral region at approximately 66-75% (43,44). In our study the commonly 
involved area was the lumbar spine at 46% followed by the lumbo sacral (L5S1 vertebra) and 
sacral spines at 25% each.  
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Genitourinary system: Scarring and renal failure is the most common cause of late death in 
patients with spina bifida aperta. The damage to the kidneys in these children may start as early 
as 6 months of age. The incidence of renal damage (scarring) in various studies has ranged 
from 4-36%. Lewis et al reported the overall prevalence of renal parenchymal damage in 
children with spina bifida as 19.4%. Another interesting observation made in the same study 
was that the prevalence of renal damage in children who were 10 years or more was 27.3% 
while the prevalence in those less than 5 years was only 13.3% (45). Kari et al reported renal 
scarring to be 36% at five years (46). The incidence of death due to renal damage in children 
with spina bifida aperta is around 20% (9,47).  
In our study it was found that 26 out of 68 children [38.24%] had upper tract dilatation and the 
prevalence across age groups beyond infancy was ranging from 30-38%. There were 19 
children who were one year or less at the time of evaluation and 4 of them [21.05%] had upper 
tract dilatation. The number of children who were 5 years or less at the time of evaluation was 
43 and 12 of them [27.90%] had upper tract dilatation.  
The time of development of upper tract dilatation for children who were beyond infancy was 
obtained from the records  and we noticed that 2 out of 49 children (4.08%) developed upper 
tract dilatation by the age of one year. 15 of the 49 children [30.61%] developed upper tract 
dilatation by the time they were five years old. This was also comparable to the literature 
values. However a DMSA scan to document scarring was done only in 5 out of the 68, none of 
whom were infants. 
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The incidence of urinary incontinence in children with spina bifida aperta without intervention 
has varied from 46-80% as per different studies (26,48,49). In our study 20 out of the 29 
children [68.96%] who were five years or more had urinary incontinence and only one child 
was able to void without accidents. This was found to be comparable with other studies given 
in literature.   
Clean intermittent catheterization (CIC) in combination with anticholinergics like oxybutynin 
is the initial therapy in children with spina bifida associated neurogenic bladder and detrusor 
sphincter dyssynergia. It has been found that in the absence of treatment a large majority of 
children with detrusor sphincter dyssynergia will develop upper tract changes. The advantage 
of CIC is that it allows for complete bladder emptying thereby reducing the chance of infection 
and prevents high pressure voiding which is detrimental to kidney function.  Oxybutynin 
relaxes the bladder preventing the high pressure bladder storage and high pressure detrusor 
contractions.  Surgery is indicated in cases where CIC and drugs were found to be ineffective.  
Of the 26 patients who were on CIC without augmentation of the bladder, 25 used the urethra 
for catheterization while a Mitrofanoff was employed in a female who found it difficult to 
catheterize per urethrally.  
14 patients were on CIC in association with bladder augmentation. 13 of the 14 patients 
performed CIC through an appendicular Mitrofanoff while the remaining 1 patient used the 
urethra.  
Malone et al in their study noted that the incidence of urinary diversion procedures like 
ureterostomy, vesicostomy and bladder augmentation, done in cases of spina bifida associated 
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neurogenic bladder was 26% (49). In our study diversion procedures were needed in 14 out of 
68 patients [23.52%] and it was found to be comparable to other studies.   
Gastrointestinal system: The incidence of bowel incontinence in children with spina bifida 
aperta varies from 13-71% according to different studies (26,27). In our study 18 of the 29 
children [62.06%] who were five years or more and 19 of the 31 children [61.29%] who were 
four years or more had soiling/ bowel incontinence.  11 of the 31 children [35.48%] who were 
4 years or more were on bowel washes. 8 of these 11 children [72.7%] who were on bowel 
wash programme had soiling or accidents. This value also concurred with the literature.  
Central nervous system: The rates of meningomyelocoele associated hydrocephalus in 
literature are extremely high at 80% (50). It is also stated that the majority of children requiring 
shunt surgery will do so by five months of age (8). In our study the total number of patients 
with symptomatic hydrocephalus that required shunting was 8 [11.76%]. Such wide 
discrepancy in the incidence rates of hydrocephalus in Indian population as compared to the 
West is surprising and needs to be investigated. The incidence of mental retardation in 
literature is around 20% (51,52), however we could not find any case of mental retardation in 
our study cohort. 
Musculoskeletal system:  Singh et al reported the  incidence of locomotory problems as 55% 
with 62% of them being independent with aids (53). In our study musculoskeletal problems 
like immobility, pressure sores and contractures were seen in 27 of the 42 children [64.28%] 
who were more than two years old.  26 children [61.90%] of this group was independent (2 of 
them used AFO’s). This almost concurred with the values in literature.  
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Sandler in his 2010 study reported the incidence of CTEV in children with spina bifida aperta 
as 50% and DDH as 25-50% (54). In our study 10 of the 68 children [14.70%] had CTEV and 
11 children had DDH [16.17%]. These values were substantially lesser on comparing with 
International standards. The most common spinal anomaly excluding kyphoscoliosis is a 
hemivertebra as per literature (55).  
Quality of life (QoL) measures: The quality of life in children who were five years or more 
was studied. As the model of QoL was believed to be mainly related to continence, it was 
decided to administer the QoL instruments to children who were more than 5 years. Four 
instruments namely the Barthel activities of daily living index, PIN-Q to measure the urinary 
incontinence related quality of life, a visual analogue scale (VAS) to measure the general 
quality of life and a patient generated index were used. The concept of a patient generated 
index proved to be too complex for our cohort and hence was not used.  
It was seen that 8 out of the 29 children had a poor quality of life across all three instruments. 
The factors which correlated to a poor quality of life in these children were bladder and bowel 
incontinence and immobility.  
On comparing the QoL scores obtained on all three instruments (PIN-Q, Barthel,VAS) for 
children with incontinence and mobility problems versus children with only incontinence, the 
median QoL scores obtained in the Barthel and VAS were better for those with incontinence 
alone (18 and 70 respectively) as opposed to those with incontinence and mobility problems 
(11 and 50 respectively). This trend seems to support the construct that incontinence and 
mobility problems contribute to QoL. The QoL that was estimated by PIN-Q was found to be 
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almost similar (52 in incontinence alone and 55 in patients with incontinence and mobility 
issues) in the two groups. However the association that QoL scores decrease as co-morbidities 
increase was not found to be statistically significant. 
Further an attempt was made to see whether there was a statistically significant correlation 
between PIN-Q and renal changes and whether higher score of PIN-Q corresponded with renal 
dilatation. No statistically significant association was found between the two.  
The results concurred with known international standards in almost all areas except for the 
reduced incidence of symptomatic hydrocephalus and associated anomalies like CTEV and 
DDH. Comparison with other Indian studies was not possible as studies from our country on 
spina bifida aperta have been few. Further studies will be required to authenticate this finding 
and search for any reason why this may be true for children from the Indian sub-continent.  
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CONCLUSION 
 
This cross sectional study revealed in our cohort that meningomyelocoele was the commonest 
spina bifida aperta lesion and it mostly affected the lumbar and sacral regions.  
The prevalence rate of upper tract dilatation in our cohort was 38.24%. The prevalence rate of 
upper tract dilatation in infants was 21.05% and in children who were 5 years or less was 
27.90%.   
The time of development of upper tract dilatation in the rest of the children who were not 
infants at the time of evaluation was noted.  4.08% of children developed upper tract dilatation 
by the age of one year and 30.61% developed upper tract dilatation by the time they were five 
years old. Upper tract dilatation needs to be further evaluated by MCU and EMG to identify 
patients at risk. 
The prevalence of various morbidities was as follows: urinary incontinence in children who 
were 5 years or more was 68.9%. Bowel incontinence in children who were 4 years or more 
was 61.29%. 55.17% of children who were 5 years or more had both bowel and bladder 
incontinence. Ambulatory problems in children who were 2 years or more were 38.09%. The 
prevalence rate of hydrocephalus in the entire cohort of 68 patients was 11.76% which was 
distinctly different from western studies. None had mental retardation.  
58.82% of children from the entire cohort were on CIC with majority using a Mitrofanoff. 
Timed double voiding was done by one child.  35.48% of children who were 4 years or more 
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were on bowel washes. 72.7% of children who were on bowel wash programme had soiling or 
accidents leaving much to be desired of this. 
Health related quality of life was evaluated in children with spina bifida aperta who were five 
years or more. Of all the quality of life instruments the visual analogue score was the most 
easily administrable and the most easily comprehensible score. Despite 81% of children having 
incontinence and 55% of children having mobility issues their global QoL as measured by the 
median visual analogue score was 70.  
It was found that 8 of the 29 children (27.6%) had a very poor quality of life which 
corresponded to the 25th centile of the scores and it correlated with them having urinary 
incontinence, fecal incontinence and immobility. A good quality of life which corresponded to 
the 75th centile was seen in 7 of the 29 (24.1%) children. Further measures to improve the 
quality of life are the need of the hour in such children.  
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Limitation of the study:  
The major limitation of this study was that a patient perspective of issues contributing to the 
quality of life could not be obtained. It calls for a better instrument to measure the quality of 
life in children with spina bifida aperta.  
Compliance with bladder and bowel management was self reported and could not be verified 
by a neutral third party observer. 
Upper tract dilatation as evidenced by ultrasound is a crude measure of renal damage. A 
DMSA scan which gives an accurate measure of renal damage was done only in 25% of the 
total cohort. 
 
Scope for further research: This study opens out further possibilities for research namely: 
- To develop a better open ended instrument to study the quality of life. 
- A larger study to correlate quality of life scores with clinical outcomes. 
- A study in which DMSA scan is done in all patients to look for renal scarring.  
- To develop a better bowel management program.     
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MASTER CHART
GROUP HOSPITAL NO GENDER DOB AGE AT EXAMINATIONDATE OF FIRST VISIT OTHER VISIT DATES CURRENT AMBULATORY STATUSAMBULATION AIDS IF ANY
1 449318F F 01.09.2002 11 YEARS  01.04.2013 18/10/2013 INDEPENDENT NO
1 036499F F 15.06.2008 05 YEARS 17.10.2011 19/3/2012; 18/2/2013;25/10/2013INDEPENDENT NO
1 686036F M 24.11.2008 05 YEARS 25.09.2013 2/10/2013 INDEPENDENT NO
1 215743D F 01.01.2008 05 YEARS 10.04.2008 12/11/2008; 9/09/2013 CARRIED PARENTAL AID
1 184775F M 13.07.2005 08 YEARS 17.04.2012 21/10/2013 INDEPENDENT AFO
1 579196B F 26.01.1998 15 YEARS 07.02.2002 20/8/2013;17/1/2014 CARRIED PARENTAL AID
1 560231B M 14.11.1997 16 YEARS 14.11.1997 5/5/2001; 10/11/2005; 21/09/2006;16/04/2007;26/12/2008;13/11/2009;29/12/2010;9/9/2011;16/7/2012;9/9/2013INDEPENDENT NO
1 085634D M 20.08.2007 06 YEARS 20.08.2007 14/9/2009; 31/5/2010; 11/5/2011; 11/5/2012; 7/6/2013INDEPENDENT NO
1 473317D F 09.10.1997 16 YEARS 02.06.2009 11/5/2010; 21/6/2011; 11/8/2012; 19/10/2013INDEPENDENT NO
1 196304D F 04.03.2008 05 YEARS 31.03.2008 4/03/2009; 20/11/2012; 9/07/2013CARRIED PARENTAL AID
1 369399C M 29.01.2003 10 YEARS 21.09.2004 22/10/2005; 18/06/2009; 7/10/2011; 30/05/2013INDEPENDENT PARENTAL AID
1 440797F F 25.04.2001 12 YEARS 28.03.2013 8/10/2013 INDEPENDENT NO
1 452904F M 20.04.2003 10 YEARS 06.04.2013 . INDEPENDENT NO
1 622532D F 12.08.2008 05 YEARS 02.02.2010 23/04/2011; 29/01/2013;20/08/2013INDEPENDENT NO
1 845107C F 21.06.2006 08 YEARS 22.06.2006 10/05/2007, 29/05/2008, 21/01/2011, 7/10/2013, 17/01/2014CARRIED PARENTAL AID
1 746737F M 02.06.2008 05 YEARS 06.12.2013 . CARRIED PARENTAL AID
1 135144F M 05.08.2008 05 YEARS 15.02.2012 18/07/2012; 8/02/2013; 28/12/2013INDEPENDENT NO
1 212542F M 25.06.2006 07 YEARS 24.05.2012 26/3/2013; 19/12/2013 CARRIED PARENTAL AID
1 845107C F 20.06.2006 07 YEARS 20.06.2006 27/09/2007; 25/08/2008; 4/10/2013CARRIED PARENTAL AID
1 499755D M 22.11.2004 09 YEARS 17.07.2009 11/6/2013 INDEPENDENT NO
1 365223C F 13.10.2003 10 YEARS 13.10.2003 2/12/2004; 31/3/2005; 20/3/2006; 22/6/2007;22/12/2008; 19/6/2009; 12/8/201124/8/201214/6/2013; 11/10/2013; 8/1/2014INDEPENDENT PARENTAL AID
1 735584C F 02.05.2003 10 YEARS 23.11.2005 14/03/2006; 28/2/2007; 14/7/2008; 26/9/2009; 28/9/2010; 18/10/2011; 10/3/2012; 22/10/2013; 25/1/2014INDEPENDENT NO
1 029535D M 21.05.2007 06 YEARS 21.05.2007 24/11/2008; 11/11/2009; 29/9/2010; 18/7/2011; 24/9/2012; 9/9/2013INDEPENDENT NO
1 425443C M 20.12.1996 17 YEARS 09.02.2004 12/11/2013 INDEPENDENT NO
1 634528C F 10.01.2005 08 YEARS 11.05.2005 20/6/2007; 28/2/2008; 7/11/2009; 19/11/2010; 11/7/2011; 10/8/2012; 1/2/2013INDEPENDENT NO
1 316232F M 27.05.2005 08 YEARS 08.10.2012 7/2/2013; 6/7/2013; 21/1/2014INDEPENDENT NO
1 433405C M 30.12.2003 10 YEARS 26.02.2004 23/8/2005; 2/8/2010; 10/6/2011; 20/4/2012; 26/4/2013; 20/11/2013INDEPENDENT AFO 
1 915297C F 27.10.2006 07 YEARS 28.10.2007 12/4/2008; 7/3/2010; 12/12/2011; 14/2/2013INDEPENDENT NO
1 850299B F 05.10.1990 23 YEARS 18.10.2004 9/5/2005; 30/6/2006; 16/7/2007; 23/6/2008; 27/4/2009; 5/12/2013; 30/1/2014INDEPENDENT NO
2 524698D M 13.08.2009 48 MONTHS 21.08.2009 7/12/2011; 31/8/2012; 20/8/2013CARRIED PARENTAL AID
2 901394D M 01.04.2011 30 MONTHS 02.04.2011 27/9/2011;2/2/2012 14/07/2012;8/01/2013; 1/06/2013; 22/10/2013CARRIED PARENTAL AID
2 046187F M 12.10.2011 27 MONTHS 12.10.2011 30/8/2012;11/1/2013;27/9/2013; 3/1/2014CARRIED PARENTAL AID
2 254189F M 10.10.2011 27 MONTHS 09.09.2013 22/1/2014 CARRIED PARENTAL AID
2 657532F F 07.02.2013 10 MONTHS 30.08.2013 21/10/2013, 22/11/2013, 6/12/2013CARRIED PARENTAL AID
2 650979F M 08.08.2013 04 MONTHS 16.08.2013 4/09/2013, 13/12/2013 CARRIED PARENTAL AID
2 646574F M 06.08.2013 04 MONTHS 13.08.2013 2/12/2013 CARRIED PARENTAL AID
2 664476F F 07.09.2013 02 MONTHS 11.09.2013 28/10/2013 CARRIED PARENTAL AID
2 707454F M 22.10.2013 02 MONTHS 22.11.2013 7/12/2013 CARRIED PARENTAL AID
2 354323F M 24.11.2012 12 MONTHS 24.11.2012 5/1/2013, 7/5/2013, 7/11/2013CARRIED PARENTAL AID
2 354313F M 24.11.2012 14 MONTHS 24.11.2012 4/7/2013, 7/1/2014 CARRIED PARENTAL AID
2 382188F M 22.07.2010 36 MONTHS 08.01.2013 2/2/2013, 4/7/2013 CARRIED PARENTAL AID
2 014227F M 21.08.2011 22 MONTHS 01.09.2011 19/03/2013 27/6/2013 CARRIED PARENTAL AID
2 678101F M 20.08.2013 05 MONTHS 14.09.2013 7/1/2014 CARRIED PARENTAL AID
2 664394F F 24.09.2013 03 MONTHS 24.09.2013 5/12/2013 CARRIED PARENTAL AID
2 688202F M 25.10.2013 03 MONTHS 25.10.2013 12/1/2014 CARRIED PARENTAL AID
1
2 628536F M 28.05.2013 03 MONTHS 18.07.2013 5/8/2013 CARRIED PARENTAL AID
2 639918F F 25.08.2013 04 MONTHS 04.09.2013 11/12/2013 CARRIED PARENTAL AID
2 644871F M 12.02.2013 06 MONTHS 08.08.2013 . CARRIED PARENTAL AID
2 647510F M 14.07.2013 06 MONTHS 10.08.2013 23/1/2014 CARRIED PARENTAL AID
2 631586F M 18.06.2013 01 MONTH 27.07.2013 . CARRIED PARENTAL AID
2 637066F F 02.09.2012 14 MONTHS 29.07.2013 18/11/2013 CARRIED PARENTAL AID
2 361994F M 17.11.2012 09 MONTHS 07.02.2013 10/8/2013 CARRIED PARENTAL AID
2 421942F M 26.02.2013 05 MONTHS 26.02.2013 4/7/2013 CARRIED PARENTAL AID
2 180418F F 21.04.2012 09 MONTHS 21.04.2012 11/1/2013 CARRIED PARENTAL AID
2 214061F F 05.05.2012 19 MONTHS 07.06.2012 3/12/2013 CARRIED PARENTAL AID
2 261399F M 22.06.2012 11 MONTHS 02.08.2012 26/4/2013,  30/05/2013 CARRIED PARENTAL AID
2 828876D F 15.11.2010 37 MONTHS 16.11.2010 10/05/2011; 27/12/2011; 12/06/2012; 28/05/2013; 24/12/2013INDEPENDENT NO
2 333048F M 24.08.2012 10 MONTHS 26.10.2012 23/1/2013; 12/6/2013 CARRIED PARENTAL AID
2 337933F M 20.07.2012 16 MONTHS 02.11.2012 28/5/2013; 26/11/2013 CARRIED PARENTAL AID
2 350584F M 12.11.2012 14 MONTHS 19.11.2012 24/6/2013; 8/1/2014 CARRIED PARENTAL AID
2 127469F F 09.09.2011 24 MONTHS 17.02.2012 16/09/2013 CARRIED PARENTAL AID
2 804379D M 24.10.2010 31 MONTHS 23.10.2010 28/02/2012;14/5/2013 CARRIED PARENTAL AID
2 770126D M 29.08.2010 31 MONTHS 30.08.2010 6/6/2011; 16/12/2011; 5/3/2012; 5/10/2012; 27/3/2013INDEPENDENT NO
2 086903F M 08.11.2011 27 MONTHS 30.11.2011 3/12/2012, 7/2/2014 INDEPENDENT NO
2 925175D M 10.04.2011 31 MONTHS 15.04.2011 11/5/2012; 25/01/2013; 8/11/2013CARRIED PARENTAL AID
2 973118D F 21.06.2011 19 MONTHS 30.06.2011 24/1/2012; 22/1/2013 CARRIED PARENTAL AID
2 924269D M 21.04.2011 34 MONTHS 02.05.2011 13/9/2011; 23/1/2012; 27/7/2012; 14/1/2013; 13/2/2014INDEPENDENT NO
2 710241D M 20.12.2009 50 MONTHS 01.06.2010 19/6/2012; 22/1/2013; 23/5/2013; 3/9/2013; 3/2/2014CARRIED PARENTAL AID
2
ANC DIAGNOSIS PLACE OF DELIVERY TYPE OF DELIVERY GESTATIONAL AGE AT DELIVERYBIRTH WEIGHT TYPE OF LESION VERTEBRAL LEVELS INVOLVEDEUROLOGICAL PROBLEMSCDH
NO INSTITUTIONAL NORMAL 38 WEEKS 3.5 KG MMC LUMBAR & SACRAL NO UNILATERAL 
NO INSTITUTIONAL NORMAL 37 WEEKS 2.3 KG MMC SACRAL NO NO
NO INSTITUTIONAL LSCS- TRANSVERSE LIE40 WEEKS 3.5 KG MMC SACRAL NO NO
NO INSTITUTIONAL LSCS- PREVIOUS CS 40 +2 WEEKS 3.5 KG MMC SACRAL HYDROCEPHALUS BILATERAL
NO INSTITUTIONAL LSCS 36 WEEKS 2.5 KG MMC LUMBAR & SACRAL HYDROCEPHALUS BILATERAL
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MMC LUMBAR & SACRAL NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.8 KG MMC SACRAL NO NO
NO INSTITUTIONAL LSCS 40 WEEKS 3.75 KG MMC SACRAL NO NO
YES INSTITUTIONAL NORMAL 36 WEEKS 3.2 KG MMC LUMBAR NO NO
NO INSTITUTIONAL LSCS 40 WEEKS 3.0 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 38 WEEKS 2.5 KG LMC LUMBAR & SACRAL NO UNILATERAL 
NO INSTITUTIONAL NORMAL 40 WEEKS 2.0 KG MMC SACRAL NO NO
NO INSTITUTIONAL LSCS 40 WEEKS 2.5 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 39 WEEKS 3.5 KG MMC SACRAL NO NO
YES HOME NORMAL 40 WEEKS 3.0 KG MMC LUMBAR NO NO
YES INSTITUTIONAL NORMAL 32 WEEKS 2.5 KG MMC LUMBAR & SACRAL HYDROCEPHALUS NO
NO INSTITUTIONAL LSCS 37 WEEKS 2.9 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MMC LUMBAR NO NO
YES HOME NORMAL 40 WEEKS 2.5 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 38  WEEKS 2.5 KG LMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.5 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.5 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 39 WEEKS 2.7 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.5 KG MMC SACRAL NO NO
YES INSTITUTIONAL NORMAL 36 WEEKS 1.7 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.5 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 42 WEEKS 3.5 KG MMC LUMBAR AND SACRALNO NO
YES INSTITUTIONAL LSCS 37 WEEKS 2.5 KG MMC SACRAL HYDROCEPHALUS NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.0 KG MMC LUMBAR AND SACRALNO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MMC LUMBAR & SACRAL NO BILATERAL
NO INSTITUTIONAL NORMAL 37 WEEKS 2.0 KG MMC LUMBAR AND SACRALNO NO
NO INSTITUTIONAL LSCS 40 WEEKS 3.25 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.50 KG LMC LUMBAR NO UNILATERAL LEFT
NO INSTITUTIONAL NORMAL 37 WEEKS 3.50 KG MMC LUMBAR AND SACRALHYDROCEPHALUS BILATERAL
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MMC LUMBAR NO NO
YES INSTITUTIONAL NORMAL 36 WEEKS 2.75 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 37 WEEKS 3.25 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 39 WEEKS 3.5 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MC SACRAL NO NO
NO INSTITUTIONAL NORMAL 36 WEEKS 2.5 KG MMC LUMBAR AND SACRALNO BILATERAL
NO INSTITUTIONAL NORMAL 37 WEEKS 2.75 KG MMC LUMBAR HYDROCEPHALUS BILATERAL
NO INSTITUTIONAL LSCS 35 WEEKS 2.25 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MMC LUMBAR AND SACRALNO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.2 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 36 WEEKS 2.75 KG MMC THORACIC NO NO
3
NO INSTITUTIONAL NORMAL 39 WEEKS 3.0 KG MMC LUMBAR NO NO
NO INSTITUTIONAL LSCS 40 WEEKS 3.0 KG MMC LUMBAR NO NO
NO INSTITUTIONAL LSCS 35 WEEKS 2.5 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.25 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 38 WEEKS 3.0 KG MC LUMBAR NO NO
NO INSTITUTIONAL LSCS 37 WEEKS 3.5 KG MMC LUMBAR AND SACRALNO NO
YES INSTITUTIONAL LSCS 37 WEEKS 3.0 KG LMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 38 WEEKS 3.0 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.25 KG MC THORACIC NO NO
NO INSTITUTIONAL NORMAL 38 WEEKS 3.0 KG MMC LUMBAR NO UNILATERAL LEFT
NO INSTITUTIONAL NORMAL 40 WEEKS 3.25 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.75 KG MC THORACIC NO NO
NO INSTITUTIONAL LSCS 37 WEEKS 3.0 KG MMC LUMBAR AND SACRALNO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 3.0 KG MMC LUMBAR AND SACRALNO NO
YES INSTITUTIONAL NORMAL 38 WEEKS 2.75 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.25 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.5 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.5 KG MMC LUMBAR NO NO
NO INSTITUTIONAL LSCS 39 WEEKS 2.25 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 40 WEEKS 2.25 KG MMC LUMBAR AND SACRALNO NO
NO INSTITUTIONAL LSCS 40 WEEKS 2.75 KG MMC LUMBAR NO NO
NO INSTITUTIONAL NORMAL 38 WEEKS 3.0 KG MMC SACRAL NO NO
NO INSTITUTIONAL NORMAL 36 WEEKS 3.9 KG MMC LUMBAR AND SACRALNO BILATERAL
4
CTEV SECONDARY SPINAL ABNORMALITYOTHE  ANOMALIES FAMILIAL AND CHROMOSOMAL ANOMALIESTYPE OF REPAIR DATE OF SURGERY VP SHUNT DATE OF VP SHUNT SURGERYPOST OP COMPLICATIONS
NO NO NO NO PRIMARY CLOSURE Mar-03 YES Mar-03 INFECTION
NO NO NO NO PRIMARY CLOSURE Jul-08 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Dec-08 NO N/A NO
NO NO NO NO PRIMARY CLOSURE May-08 YES May-08 NO
BILATERAL NO SEIZURE NO PRIMARY CLOSURE Jul-05 YES Oct-05 NO
BILATERAL YES NO NO NO . NO N/A NO
NO NO NO NO PRIMARY CLOSURE Nov-97 NO N/A INFECTION
NO NO NO NO PRIMARY CLOSURE Aug-07 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-97 NO N/A NO
BILATERAL NO NO NO FLAP CLOSURE Mar-08 NO N/A INFECTION
BILATERAL NO ARM WITH RIGHT UDT AND RIGHT FIBULAR HEMIMELIANO PRI ARY CLOSURE Feb-03 NO N/A INFECTION
NO NO NO NO PRIMARY CLOSURE Jul-01 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-03 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Aug-08 NO N/A NO
UNILATERAL NO SHORTENING OF LEFT LLNO PRIMARY CLOSURE Jun-06 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Jun-08 YES Sep-08 NO
NO NO NO NO PRIMARY CLOSURE Aug-08 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Jun-06 NO N/A NO
NO NO LEFT LOWER LIMB PARALYSISNO PRIMARY CLOSURE Jun-06 NO N/A NO
NO NO NO NO NO . NO N/A N/A
NO NO NO NO PRIMARY CLOSURE Oct-03 NO N/A NO
NO NO PARTIAL SACRAL AGENESISNO PRIMARY CLOSURE Nov-03 NO N/A NO
NO NO NO NO PRIMARY CLOSURE May-07 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Dec-96 NO N/A NO
NO NO NO NO PRIMARY CLOSURE May-05 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-05 NO N/A NO
UNILATERAL NO NO NO PRIMARY CLOSURE Jan-04 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-06 YES Jun-09 NO
NO NO NO NO NO . NO N/A N/A
BILATERAL YES NO NO PRIMARY CLOSURE Aug-09 NO N/A INFECTION
NO NO NO NO PRIMARY CLOSURE Apr-11 NO N/A INFECTION
NO NO NO NO PRIMARY CLOSURE Oct-11 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Sep-13 YES Dec-13 INFECTION, MENINGITIS
NO NO NO NO PRIMARY CLOSURE Aug-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Sep-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Dec-13 NO N/A INFECTION
NO NO NO NO PRIMARY CLOSURE Oct-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Nov-12 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Nov-12 NO N/A INFECTION, URINARY RETENTION
BILATERAL NO HYPOSPADIAS NO PRIMARY CLOSURE Jul-10 YES Sep-10 NO
NO NO LEFT UDT NO PRIMARY CLOSURE Aug-11 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Sep-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Sep-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-13 NO N/A NO
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NO NO NO NO PRIMARY CLOSURE Jul-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Sep-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Aug-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Aug-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Aug-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Aug-13 NO N/A INFECTION
NO NO NO NO PRIMARY CLOSURE Jan-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Jun-13 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Apr-12 NO N/A NO
NO NO NO NO PRIMARY CLOSURE May-12 NO N/A NO
NO NO CROSSED FUSED LEFT KIDNEYNO PRIMARY CLOSURE Aug-12 YES Apr-13 NO
NO NO NO NO PRIMARY CLOSURE Nov-10 NO N/A NO
UNILATERAL NO NO NO PRIMARY CLOSURE Oct-12 NO N/A INFECTION, MENINGITIS
NO NO NO NO PRIMARY CLOSURE Nov-12 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Nov-12 NO N/A NO
NO NO ARTHROGRYPHOSIS B/L LOWER LIMBSNO PRIMARY CLOSURE Feb-12 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Oct-10 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Aug-10 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Nov-11 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Apr-11 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Jul-11 NO N/A NO
NO NO NO NO PRIMARY CLOSURE Apr-11 NO N/A NO
BILATERAL NO SOLITARY RIGHT KIDNEYO NO N/A NO N/A NO
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IMMEDIATE POST OP NEUROLOGYHC WEIGHT HEIGHT MOTOR - HIP KNEE ANKLE CONTRACTURES SENSORY SORE
NOT SURE 44 CM 29 KG 139 CM YES YES YES NO YES
NOT SURE 43 CM 23 KG 108 CM YES YES YES NO NO
NOT SURE 42 CM 13 KG 91 CM YES YES YES NO YES
NOT SURE 55 CM 12 KG 94 CM YES YES YES YES NO
NOT SURE 49 CM 22 KG 108 CM YES YES NO NO NO
NO 54 CM 19 KG 128 CM NO NO NO YES YES
NOT SURE 48 CM 42 KG 152 CM YES YES YES NO YES
NOT SURE 54 CM 21 KG 116 CM YES YES YES NO NO
NO CHANGE 55 CM 52 KG 142 CM YES YES YES YES NO
NOT SURE 47 CM 14 KG NO NO NO NO YES
NOT SURE 54 CM 40 KG YES YES YES NO NO
NOT SURE 55 CM 38 KG 145 CM YES YES YES NO NO
NOT SURE 49 CM 20 KG 130 CM YES YES NO NO YES
NOT SURE 48 CM 18 KG 126 CM YES YES YES NO NO
NOT SURE 54 CM 18 KG 102 CM YES NO NO YES NO
NOT SURE 51 CM 12 KG 90 CM YES YES NO NO NO
NOT SURE 54 CM 18 KG 105 CM YES YES YES NO NO
NOT SURE 52 CM 18 KG 110 CM YES YES- RIGHT NO NO YES
NOT SURE 51 CM 17 KG 103 CM YES NO(L); YES® NO(L); YES® NO(L); YES® YES
N/A 48 CM 16 KG 111 CM YES YES YES NO YES
NOT SURE 56 CM 24 KG 121 CM YES YES YES NO NO
NOT SURE 54 CM 21 KG 122 CM YES YES YES NO NO
NOT SURE 42 CM 16 KG 109 CM YES YES YES NO YES
NOT SURE 54 CM 37 KG 160 CM YES YES YES NO NO
NOT SURE 50 CM 14 KG 91 CM YES YES YES NO NO
NO CHANGE 49 CM 20 KG 120 CM YES YES YES NO NO
NOT SURE 53 CM 24 KG 117 CM YES YES NO NO YES
NO CHANGE 52 CM 13 KG 92 CM YES YES YES NO NO
N/A 54 CM 36 KG 150 CM YES YES NO NO YES
NOT SURE 48 CM 16 KG 104 CM NO NO NO YES YES
NOT SURE 44 CM 12 KG 83 CM YES YES YES NO NO
NOT SURE 48 CM 13 KG 84 CM YES YES NO NO NO
NOT SURE 46 CM 10 KG 87 CM YES YES NO NO NO
NOT SURE 48 CM 5.25 KG 56 CM NO NO NO NO NO
NOT SURE 37 CM 5.5 KG 57 CM YES YES NO NO NO
NOT SURE 37 CM 5.0 KG 55 CM YES YES YES NO NO
NOT SURE 34 CM 4.0 KG 47 CM YES YES YES NO NO
NOT SURE 38 CM 4.5 KG 57 CM YES YES YES NO NO
NOT SURE 42 CM 9 KG 74 CM YES YES YES NO NO
DETERIORATED 44 CM 8 KG 71 CM NO NO NO NO NO
DETERIORATED 51 CM 9 KG 80 CM NO NO NO NO YES
NOT SURE 47 CM 12 KG 86 CM YES YES NO NO NO
NOT SURE 38 CM 5 KG 54 CM YES YES NO NO NO
NOT SURE 36 CM 4.5 KG 54 CM YES YES NO NO NO
NOT SURE 36 CM 4.5 KG 53 CM YES YES YES NO NO
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NOT SURE 38 CM 4.0 KG 54 CM YES YES NO NO NO
NOT SURE 38 CM 5.0 KG 55 CM YES YES NO NO NO
NOT SURE 40 CM 6.0 KG 60 CM YES YES NO NO NO
NOT SURE 41 CM 8.25 KG 62 CM YES YES NO NO NO
NO CHANGE 35 CM 4.0 KG 48 CM YES YES YES NO NO
DETERIORATED 46 CM 10 KG 73 CM YES NO NO NO NO
NOT SURE 44 CM 9.5 KG 73 CM YES YES NO NO NO
NOT SURE 38 CM 5.0 KG 54 CM YES YES NO NO NO
NO CHANGE 42 CM 8.5 KG 64 CM YES YES YES NO NO
NO CHANGE 47 CM 11 KG 76 CM YES NO NO NO NO
NO CHANGE 49 CM 7.6 KG 69 CM YES YES NO NO NO
NOT SURE 52 CM 13 KG 85 CM YES YES YES NO NO
NOT SURE 45 CM 11 KG 74 CM YES YES NO NO NO
NOT SURE 44 CM 10 KG 72 CM YES YES YES NO NO
NO CHANGE 49 CM 10 KG 74 CM YES YES NO NO NO
NOT SURE 50 CM 11 KG 77 CM NO YES NO NO NO
NO CHANGE 52 CM 13 KG 80 CM YES YES NO NO NO
NO CHANGE 51 CM 14 KG 84 CM YES YES YES NO NO
NO CHANGE 49 CM 11 KG 82 CM YES YES YES NO NO
NOT SURE 46 CM 9 KG 76 CM YES YES NO NO NO
NOT SURE 43 CM 6 KG 73 CM YES NO NO NO NO
NO CHANGE 44 CM 9 KG 79 CM YES YES YES NO NO
N/A 46 CM 11 KG 82 CM YES NO NO NO NO
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LEVEL OF SENSATIONSADDLE ANAESTHESIANAL TONE BULBO CAVERNOUS REFLEXANAL SENSATION BLADDER SENSATIONBLADDER PALPABLE BLADDER EXPRESSIBLEDATE
BILATERAL ANKLE NO NO NO NO NO NO NO 1/4/2013
FULLY SENSATE NO NO NO NO NO NO NO 18/10/2011
BILATERAL ANKLE NO NO NO NO NO NO NO 26/9/2013
BILATERAL THIGH YES NO NO NO YES NO NO 12/11/2008
BILATERAL KNEE NO NO NO NO NO NO NO 18/4/2012
BILATERAL HIPS YES NO NO NO NO NO YES 20/8/2013
BILATERAL FOOT NO NO NO YES NO NO NO 19/4/2005
BILATERAL FOOT NO NO NO YES YES NO NO 22/08/2007
FULLY SENSATE NO NO NO YES NO NO NO 30/9/2009
BILATERAL HIPS YES NO NO NO NO NO YES 5/3/2008
BILATERAL MID THIGHYES NO NO NO NO NO NO 22/10/2005
FULLY SENSATE NO NO NO NO NO NO NO 28/3/2013
BILATERAL THIGHS YES NO NO NO NO NO NO 6/4/2013
BILATERAL ANKLES NO NO NO NO NO NO NO 2/2/2010
BILATERAL HIPS YES NO NO NO NO NO NO 22/06/2006
BILATERAL THIGHS YES NO NO NO NO NO YES 29/11/2013
FULLY SENSATE NO NO NO YES YES NO NO 15/02/2012
BILATERAL KNEES YES NO NO NO NO NO NO 24/5/2012
BILATERAL HIPS NO YES NO YES YES NO NO 22/06/2006
BILATERAL ANKLE YES NO NO YES YES NO NO 13/07/2009
BILATERAL KNEES NO NO NO YES NO NO NO 6/4/2006
FULLY SENSATE NO NO NO YES NO NO NO 24/11/2005
BILATERAL FOOT NO NO NO NO NO NO NO 24/11/2008
FULLY SENSATE NO NO NO YES YES NO NO 12/2/2004
BILATERAL FOOT NO NO NO YES NO NO NO 20/6/2007
FULLY SENSATE NO YES YES YES NO NO NO 9/10/2012
BILATERAL ANKLE NO NO NO NO NO NO YES 2/8/2010
FULLY SENSATE NO NO NO YES NO NO NO 10/4/2008
BILATERAL KNEES YES NO NO YES NO NO NO 9/5/2005
BILATERAL HIPS YES NO NO N N NO NO 21/8/2009
BILATERAL  KNEES YES NO NO NO NO NO NO 27/09/2011
BILATERAL ANKLE NO NO NO NO NO NO NO 12/10/2011
BILATERAL ANKLE NO NO NO NO NO NO NO 9/9/2013
BILATERAL HIPS YES NO NO N/A N/A NO NO 4/9/2013
BILATERAL ANKLE NO NO NO N/A N/A NO NO 4/9/2013
BILATERAL ANKLES NO NO NO N/A N/A NO NO 14/08/2013
FULLY SENSATE NO NO NO N/A N/A NO NO 11/9/2013
FULLY SENSATE NO NO NO N/A N/A NO NO 22/11/2013
FULLY SENSATE YES YES YES N/A N/A NO NO 24/11/2012
BILATERAL HIPS YES NO NO N/A N/A YES YES 4/7/2013
BILATERAL HIPS YES NO NO N/A N/A NO NO 11/2/2013
BILATERAL KNEES NO NO NO NO NO NO NO 24/08/2011
BILATERAL ANKLE YES NO NO N/A N/A NO NO 14/09/2013
BILATERAL ANKLES YES NO NO N/A N/A NO NO 24/9/2013
FULLY SENSATE NO NO NO N/A N/A NO NO 26/10/2013
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BILATERAL ANKLES NO NO NO N/A N/A NO NO 19/7/2013
BILATERAL ANKLES NO NO NO N/A N/A NO NO 4/9/2013
BILATERAL KNEES NO NO NO N/A N/A NO NO 8/8/2013
BILATERAL ANKLES NO NO NO N/A N/A NO NO 10/8/2013
FULLY SENSATE NO YES YES N/A N/A NO NO 27/7/2013
BILATERAL HIPS YES NO NO N/A N/A NO NO 29/7/2013
BILATERAL ANKLES NO NO NO N/A N/A NO NO 2/2/2013
BILATERAL ANKLES NO NO NO N/A N/A NO NO 4/6/2013
FULLY SENSATE NO YES YES N/A N/A NO NO 11/1/2013
BILATERAL HIPS YES NO NO N/A N/A NO NO 29/5/2012
BILATERAL KNEES YES NO NO N/A N/A NO NO 2/8/2012
FULLY SENSATE YES YES YES N/A N/A NO NO 16/11/2010
BILATERAL ANKLES YES NO NO N/A N/A NO NO 26/10/2012
BILATERAL FEET NO NO NO N/A N/A NO NO 8/11/2012
BILATERAL ANKLE NO NO NO N/A N/A NO NO 21/11/2012
BILATERAL KNEES NO NO NO N/A N/A NO NO 17/2/2012
BILATERAL HIPS NO NO NO N/A N/A NO NO 23/10/2010
FULLY SENSATE NO YES YES N/A N/A NO NO 7/12/2010
FULLY SENSATE NO YES YES N/A N/A NO NO 30/11/2011
BILATERAL KNEES NO NO NO N/A N/A NO NO 17/4/2011
BILATERAL KNEES NO NO NO N/A N/A NO NO 5/7/2011
FULLY SENSATE NO YES YES N/A N/A NO NO 22/4/2011
BILATERAL KNEES YES NO NO NO NO NO NO 4/12/2011
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URINE WBC 1 URINE CULTURE 1 SERUM CREATININE 1USG 1 RIGHT KIDNEY PELVISUSG 1 LEFT PELVIS PVR-1 BLADDER THICKNESS-1MCU VUR-1 PVR-1
NO NO 1.3 13 MM 30 MM NIL 3 MM LEFT GR 5 VUR YES
YES YES 0.5 NORMAL NORMAL 34 ML 3.3 MM LEFT GRADE 4 VUR YES
YES YES 1.17 33 MM 27 MM 44 ML 2 MM BILATERAL GRADE 5 VURYES
NO NO 0.5 16 MM 15 MM 0 ML 2 MM RIGHT GRADE 5 AND LEFT GRADE 2 VURYES
YES YES 0.7 5  MM 8 MM 0 ML 2 MM N/A N/A
YES YES 2.43 15 MM 15 MM 30 ML 4 MM RIGHT GRADE 4 YES
N/A N/A 0.6 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
YES YES 0.7 10 MM NORMAL 10 ML 4 MM RIGHT GRADE 3 YES
NO NO 0.6 N/A N/A N/A N/A N/A N/A
NO NO 0.6 NORMAL 20 MM 0 ML 2 MM NO YES
YES YES 0.8 NORMAL 10 MM 120 ML 4 MM NO YES
NO NO 0.61 NORMAL NORMAL 4 ML 4 MM NO NO
YES YES 0.5 NORMAL 10 MM 0 ML 4 MM LEFT GRADE 1 NO
NO NO 0.4 N/A N/A N/A N/A N/A N/A
YES YES 0.8 12 MM 11.7 MM 20 ML 2 MM BILATERAL GRADE 4 VURYES
YES YES 0.71 15 MM 23 MM 0 ML 4 MM BILATERAL GRADE 5 VURYES
YES YES 0.54 NORMAL NORMAL 6 ML 5 MM NO YES
YES YES 0.3 NORMAL NORMAL 0 ML 2 MM N/A N/A
YES NO 0.6 NORMAL NORMAL 45 ML 2 MM NO YES
NO NO 0.5 NORMAL NORMAL 30 ML 2 MM NO NO
NO NO 0.5 NORMAL NORMAL 20 ML 3.8 MM LEFT GRADE 2 YES
NO NO 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.5 NORMAL NORMAL 35 ML 5 MM NO YES
YES YES 1.3 8 MM 8 MM 5 ML 4 MM NO YES
YES YES 1.65 31 MM 25 MM 20 ML 8 MM NO YES
NO NO 0.5 NORMAL NORMAL 20 ML 3 MM NO NO
YES YES 0.4 NORMAL NORMAL 0 ML 3 MM N/A N/A
N/A N/A 0.6 NORMAL NORMAL 200 ML 3 MM N/A N/A
NO N/A 0.3 NORMAL NORMAL 3 ML 2 MM N/A N/A
NO NO 0.4 NORMAL NORMAL 0 ML 2 MM NO YES
NO NO 0.3 N/A N/A N/A N/A N/A N/A
NO NO 0.5 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.2 NORMAL NORMAL 11 ML 3 MM N/A N/A
NO NO 0.4 NORMAL NORMAL 2 ML 2 MM N/A N/A
NO NO 0.3 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.3 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.8 N/A N/A N/A N/A N/A N/A
NO NO 0.39 NORMAL NORMAL 0 ML 2 MM N/A N/A
YES YES 0.35 17.5 MM 18 MM 0 ML 3 MM BILATERAL YES
NO NO 0.44 N/A N/A N/A N/A N/A N/A
NO NO 0.2 N/A N/A N/A N/A N/A N/A
NO NO 0.3 N/A N/A N/A N/A N/A N/A
NO NO 0.23 5 MM 5 MM 0 ML 5 MM N/A N/A
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NO NO 0.39 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.2 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.5 NORMAL 5 MM 0 ML 2 MM N/A N/A
N/A N/A 0.3 N/A N/A N/A N/A N/A N/A
NO NO 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.36 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.45 N/A N/A N/A N/A N/A N/A
NO NO 0.44 NORMAL 5 MM 5 ML 3 MM N/A N/A
NO NO 0.45 NORMAL NORMAL 0 ML 2MM N/A N/A
NO NO 0.54 N/A N/A N/A N/A N/A N/A
YES YES 0.6 5 MM NONE 0 ML 3 MM N/A N/A
NO NO 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.43 NORMAL NORMAL 0 ML 2 MM N/A N/A
YES YES 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
NO NO 0.69 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 1 NORMAL NORMAL 4 ML 2 MM N/A N/A
NO N/A 0.4 NORMAL NORMAL 0 ML 2 MM N/A N/A
N/A N/A 0.3 N/A N/A N/A N/A N/A N/A
NO N/A 0.4 NORMAL NORMAL 20 ML 3 MM N/A N/A
NO NO 0.6 N/A N/A N/A N/A N/A N/A
N/A N/A 0.9 NORMAL NORMAL 0 ML 2 MM N/A N/A
YES YES 2.6 N/A N/A N/A N/A N/A N/A
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BLADDER NECK CONTRACTURE-1DMSA SPLIT L / R -1 SCAR-1 CMG- 1 DATE-2 WBC-2 CULTURE-2 SERUM CREAT-2 RIGHT PELVIS-2
NO 0 / 100 LEFT SCAR POORLY COMPLIANT HIGH PRESSURE BLADDER18/10/2013 YES NO 1.2 12 MM
NO N/A N/A N/A 19/03/2012 NO NO 0.64 N/A
NO 44 / 56 NO HIGH PRESSURE POORLY COMPLIANT BLADDERN/A N/A N/A N/A N/A
NO N/A N/A N/A 11/7/2013 NO NO 0.68 18 MM
N/A N/A N/A N/A 21/10/2013 YES YES 0.6 N/A
NO N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER17/1/2014 NO N/A 1.13 N/A
N/A N/A N/A N/A 24/12/2008 N/A N/A 0.7 5 MM
N/A N/A N/A N/A 16/12/2008 N/A N/A 0.4 NORMAL
NO N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER21/6/2011 N/A N/A 0.9 NORMAL
N/A N/A N/A N/A 4/3/2009 N/A N/A 0.5 NORMAL
NO N/A N/A N/A 20/10/2007 NO NO 0.6 N/A
NO N/A N/A POORLY COMPLIANT HIGH PRESSURE BLADDERN/A N/A N/A N/A N/A
NO N/A N/A POORLY COMPLIANT HIGH PRESSURE BLADDERN/A N/A N/A N/A N/A
NO N/A N/A N/A 11/2/2011 NO NO 0.5 NORMAL
N/A N/A N/A N/A 13/12/2013 YES YES 0.43 NORMAL
NO 55/ 45 YES HIGH PRESSURE POORLY COMPLIANT BLADDERN/A N/A N/A N/A N/A
NO 52/48 NO NORMAL 10/7/2012 YES NO 0.74 NORMAL
NO N/A N/A N/A 10/5/2013 NO NO 0.52 N/A
N/A N/A N/A N/A 13/12/2013 YES YES N/A NORMAL
NO 51/ 49 NO HYPERREFLEXIC BLADDER 12/6/2013 NO NO 0.38 NORMAL
NO N/A N/A N/A 18/6/2010 NO NO 0.5 NORMAL
NO N/A N/A N/A 12/5/2007 YES YES 0.5 NORMAL
N/A N/A N/A N/A 24/11/2009 NO NO 0.5 NORMAL
NO N/A N/A N/A 12/11/2013 YES YES 0.8 10 MM
NO N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER7/11/2009 NO N/A 0.9 NORMAL
NO 68/ 32 NO HIGH PRESSURE POORLY COMPLIANT BLADDER8/4/2013 N/A YES 1.35 22 MM
NO N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER5/10/2011 YES YES 0.5 NORMAL
N/A N/A N/A N/A 10/3/2010 YES YES 0.5 NORMAL
N/A N/A N/A N/A 23/6/2008 N/A N/A 0.7 NORMAL
N/A N/A N/A N/A 7/12/2011 NO N/A 0.5 NORMAL
NO N/A N/A N/A 2/2/2012 N/A N/A 0.44 N/A
N/A N/A N/A N/A 21/03/2012 NO NO 0.46 NORMAL
N/A N/A N/A N/A 22/01/2014 NO NO NORMAL
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A 16/12/2013 NO NO 0.2 N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A 5/1/2013 N/A N/A 0.48 NORMAL
N/A N/A N/A N/A 7/1/2014 N/A N/A 0.23 NORMAL
NO NO 49/ 51 HIGH PRESSURE POORLY COMPLIANT BLADDER27/6/2013 YES NO 0.42 NORMAL
N/A N/A N/A N/A 19/03/2013 NO NO 0.44 NORMAL
N/A N/A N/A N/A 7/1/2014 N/A N/A 0.23 NORMAL
N/A N/A N/A N/A 5/12/2013 N/A N/A N/A NORMAL
N/A N/A N/A N/A 12/1/2014 N/A N/A N/A
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N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A 24/12/2103 NO NO 0.16 NORMAL
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A 23/01/2014 NO NO 0.33 5 MM
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A 18/11/2013 NO NO 0.5 NORMAL
N/A N/A N/A N/A 8/8/2013 N/A N/A 0.4 NORMAL
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A 28/11/2013 YES YES 0.3 12.5 MM
N/A N/A N/A N/A 29/5/2013 YES YES 0.58 5 MM
N/A N/A N/A N/A 27/12/2012 N/A N/A N/A NORMAL
N/A N/A N/A N/A 30/5/2013 YES YES 0.43 NORMAL
N/A N/A N/A N/A 27/5/2013 NO NO 0.36 NORMAL
N/A N/A N/A N/A 8/1/2014 NO N/A 0.5 NORMAL
N/A N/A N/A N/A 17/9/2013 NO N/A 0.43 NORMAL
N/A N/A N/A N/A 23/5/2013 NO N/A 0.56 NORMAL
N/A N/A N/A N/A 2/12/2011 NO N/A N/A NORMAL
N/A N/A N/A N/A 3/12/2012 N/A N/A 0.42 NORMAL
N/A N/A N/A N/A 7/5/2012 NO N/A 0.9 NORMAL
N/A N/A N/A N/A 31/1/2012 N/A N/A N/A NORMAL
N/A N/A N/A N/A 9/11/2011 NO N/A 0.4 NORMAL
N/A N/A N/A N/A 21/5/2012 YES YES 4.52 25 MM
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LEFT PELVIS-2 PVR-2 BLADDER THICKNESS-2VUR-2 PVR-2 BN CONTR-2 SPLIT-2 SCAR-2 CMG-2
28 MM 60 ML 3 MM N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A 45 / 55 LEFT SCAR N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
19 MM 20 ML 6 MM BILATERAL GRADE 5 VURYES NO 37 / 63 BILATERAL POORLY COMPLIANT HIGH PRESSURE BLADDER
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
5 MM 35 ML 5 MM NO YES NO N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM GRADE 4 LEFT YES NO N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A 48/ 52 NO N/A
NORMAL 0 ML 2 MM YES- RIGHT GRADE 1 YES NO N/A N/A POORLY COMPLIANT BLADDER
N/A N/A N/A N/A N/A N/A N/A N/A N/A
3 MM NO 3 MM N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL 9 ML 2  MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2.2 MM N/A N/A N/A N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER
NORMAL 12 ML 2 MM YES- LEFT GRADE 3 YES NO N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER
25 MM 50 ML 3 MM NO YES YES 51/ 49 NO HIGH PRESSURE POORLY COMPLIANT BLADDER
5 MM 0 ML 3 MM YES YES NO N/A N/A N/A
19 MM 30 ML 8 MM N/A N/A N/A N/A N/A N/A
NORMAL 20 ML 2 MM NO NO NO N/A N/A N/A
NORMAL 0 ML 2 MM YES- RIGHT GRADE 4 YES NO 56/ 44 YES HIGH PRESSURE POORLY COMPLIANT BLADDER
NORMAL 100 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM NO NO NO N/A N/A N/
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL 25 ML 2 MM N/A N/A N/A 52/ 48 NO N/A
NORMAL 14 ML 2 MM NO NO NO N/A N/A GOOD COMPLIANT BLADDER
N/A N/A N/A N/A N/A N/A N/A N/A N/N
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM NO NO NO N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 3.5 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
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N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
5 MM 0 ML 2 MM YES NO NO N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 10 ML 3 MM N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
23.5 MM 0 ML 3 MM NO YES NO N/A N/A HIGH PRESSURE POORLY COMPLIANT BLADDER
NONE 0 ML 3 MM YES YES NO 0/ 100 NO N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM NO NO NO N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM NO YES NO N/A N/A N/A
NORMAL 0 ML 2 MM NO YES NO N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 14 ML 2.3 MM NO YES NO N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A N/A
NO 5 ML 2 MM N/A N/A N/A N/A N/A N/A
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DATE-3 WBC-3 CULTURE-3 CREATININE-3 RIGHT PELVIS-3 LEFT PELVIS-3 PVR-3 BLADDER THICKNESS-3VUR-3
N/A N/A N/A N/A N/A N/A N/A N/A N/A
18/02/2013 NO NO 0.62 NORMAL NORMAL 30 ML 2 MM N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
15/09/2013 N/A N/A 0.85 N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
2/5/2012 NO N/A 1.02 NORMAL NORMAL 30 ML 2 MM N/A
11/5/2012 N/A N/A 0.58 11 MM 11 MM 65 ML 2 MM NO
11/8/2012 N/A N/A 0.8 N/A N/A N/A N/A N/A
20/11/2012 N/A N/A 0.51 N/A N/A N/A N/A N/A
18/06/2009 N/A N/A 0.6 N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
29/01/2013 N/A N/A 0.61 NORMAL 7 MM 0 ML 2 MM NO
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
5/2/2013 NO N/A 0.75 4.6 MM NORMAL 1.5 ML 5 MM N/A
19/12/2013 YES YES 0.26 NORMAL NORMAL 5 ML 9 MM N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
29/4/2013 N/A N/A 0.7 NORMAL NORMAL 3 ML 2 MM NO
16/8/2009 N/A N/A 0.6 NORMAL NORMAL 0 ML 3.4 MM NO
24/9/2012 YES NO 0.7 7 MM NORMAL 0 ML 2 MM N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
10/8/2012 YES YES 1.1 NORMAL 8 MM N/A N/A N/A
9/10/2013 N/A N/A 0.97 17 MM 11 MM 20 ML 3 MM N/A
22/10/2012 YES YES 0.6 NORMAL NORMAL 0 ML 2 MM NO
12/10/2011 N/A N/A 0.8 20 MM 10 MM 20 ML 3 MM YES- LEFT GRADE 4
15/7/2010 NO N/A 0.7 N/A N/A N/A N/A N/A
8/10/2012 NO N/A 0.5 N/A N/A N/A N/A N/A
8/1/2013 N/A N/A 0.41 NORMAL  NORMAL 0 ML 2 MM N/A
30/09/2013 NO NO 0.44 NORMAL NORMAL 7 ML 3.2 MM YES
GOOD COMPLIANT BLADDER N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
4/5/2013 N/A N/A 0.4 NORMAL NORMAL 3.5 ML 2.4 MM N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
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N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
28/5/2013 NO NO 0.45 NORMAL NORMAL 0 ML 2 MM N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
18/9/2012 NO N/A 0.3 NORMAL NORMAL 0 ML 2 MM N/A
7/2/2014 N/A N/A 0.28 NORMAL NORMAL 30 ML 4 MM N/A
9/11/2013 NO NO N/A N/A N/A N/A N/A N/A
25/1/2013 YES NO 0.46 NORMAL NORMAL 50 ML 2 MM NO 
23/7/2012 NO N/A 0.4 NORMAL NORMAL 10 ML 2 MM N/A
11/4/2013 YES YES 1.87 17 MM NO 0 ML 2 MM N/A
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PVR-3 BN CONTR-3 SPLIT-3 SCAR-3 CMG-3 DATE-4 WBC-4 CULTURE-4 CREAT-4
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 25/10/2013 NO N/A 0.53
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 29/4/2013 NO NO 1.07
YES NO N/A N/A N/A 22/05/2013 NO NO 0.54
N/A N/A N/A N/A N/A 19/10/2013 NO N/A 0.85
N/A N/A N/A N/A N/A 9/7/2013 YES YES 0.49
N/A N/A N/A N/A GOOD COMPLIANT BLADDER30/05/2013 NO NO 0.72
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NO NO N/A N/A GOOD COMPLIANT BLADDER20/08/2013 N/A N/A 0.53
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 5/12/2013 YES NO 0.58
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NO NO N/A N/A N/A 23/9/2013 N/A N/A 0.5
YES NO 39/ 61 NO N/A 2/5/2013 YES NO 0.57
N/A N/A N/A N/A N/A 9/9/2013 NO NO 0.6
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 30/1/2013 YES NO 1
N/A N/A N/A N/A N/A 11/1/2014 N/A N/A 0.71
N/A N/A N/A N/A N/A 3/7/2013 YES YES 0.6
YES NO 46/ 54 YES N/A 16/2/2013 N/A N/A 0.88
N/A N/A N/A N/A N/A 5/11/2013 N/A N/A 0.8
N/A N/A N/A N/A N/A 19/8/2013 N/A N/A 0.5
N/A N/A N/A N/A N/A 22/10/2013 N/A N/A 0.55
YES NO N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 7/11/2013 N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
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N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 23/12/2013 NO NO 0.31
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 20/3/2013 NO N/A 0.54
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
YES NO N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A 17/1/2013 N/A N/A N/A
N/A N/A N/A N/A N/A 27/1/2014 NO NO 1.75
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RIGHT PELVIS-4 LEFT PELVIS-4 PVR-4 B THICK-4 VUR-4 PVR-4 BN CONTR-4 SPLIT-4 SCAR-4
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 3 ML 2 MM N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 10 ML 2 MM N/A N/A N/A N/A N/A
3 MM 3.7 MM 48 ML 3.6 MM N/A N/A N/A N/A N/A
NORMAL NORMAL 20 ML 2 MM N/A N/A N/A N/A N/A
NORMAL NORMAL 0 ML 5.2 MM NO YES NO N/A N/A
NORMAL 20 MM 0 ML 2 MM NO YES NO 50/ 50 NO
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 18 ML 2.7 MM NO NO NO N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A
NORMAL NORMAL 20 ML 2 MM N/A N/A N/A N/A N/A
NORMAL NORMAL 10 ML 2 MM N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
10 MM 10 MM 20 ML 2 MM N/A N/A N/A N/A N/A
NORMAL NORMAL 0 ML 2 MM YES- LEFT GRADE 3 YES NO N/A N/A
NORMAL 11 MM 20 ML 2 MM N/A N/A N/A N/A N/A
NORMAL NORMAL 20 ML 2 MM NO YES NO 46/ 54 NO
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
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N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 0 ML 2 MM N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
N/A N/A N/A N/A N/A N/A N/A N/A N/A
NORMAL NORMAL 14 ML 2 MM N/A N/A N/A N/A N/A
11 MM NO 0 ML 2 MM N/A N/A N/A N/A N/A
22
CMG-4 BLADDER CIC NIGHT DRAINAGE ADM. PORT DRUGS DRY INTERVAL CHANGE OF UNDERGARMENTS/DAYCE/ BOWEL WASH ADM PORT
N/A YES- 3 HOURLY YES URETHRA TROPAN 2.5 MG BD 2 HOURS 3-4/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA TROPAN 2.5 MG BD 2 HOURS 5/ DAY YES RECTUM
N/A YES- 3 HOURLY YES MITROFANOFF NO 2 HOURS 3-4/ DAY NO NO
N/A YES- 3 HOURLY YES MITROFANOFF NO 3 HOURS 2/ DAY NO NO
N/A YES- 3 HOURLY YES MITROFANOFF NO 30 MINUTES- LEAKS FROM MITOFANOFF4-5/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA TROPAN 1 HOUR 10/ DAY MANUAL EVACUATIONRECTUM
N/A YES- 3 HOURLY YES MITROFANOFF NO 3 HOURS 1/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA TROPAN 2.5 MG BD 3 HOURS 1-2/DAY NO N/A
GOOD COMPLIANT BLADDERYES- 4 HOURLY YES URETHRA TROPAN 4 HOURS 1-2/ DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA TROPAN 1.5 HOURS 4-5/DAY YES RECTUM
GOOD COMPLIANT BLADDERYES- 3 HOURLY YES URETHRA TROPAN; AMILENE 2 HOURS 4/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA TROPAN, AMILENE 3 HOURS 1-2/ DAY YES RECTUM
N/A YES- 3 HOURLY YES MITROFANOFF TROPAN 3 HOURS 2-3 / DAY YES RECTUM
N/A YES- 3 HOURLY YES MITROFANOFF TROPAN 3 HOURS 1-2/ DAY NO N/A
N/A NO NO NO NO 4 HOURS 4-6/ DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA NO 30 MINUTES 15/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA NO 3 HOURS 1-2/ DAY NO N/A
N/A YES- 3 HOURLY YES MITROFANOFF TROPAN 1 HOUR 6-7/ DAY YES RECTUM
N/A NO NO N/A NO 4 HOURS 1/ DAY NO N/A
N/A NO NO N/A NO 1 HOUR 5-7/ DAY NO N/A
N/A YES- 3 HOURLY YES YES TROPAN 3 HOURS 1-2/ DAY YES RECTUM
N/A YES- 4 HOURLY YES URETHRA TROPAN 2.5 MG BD 4 HOURS 2-3/ DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA TROPAN, AMILENE 30 MINUTES 4-5/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA NO 3 HOURS 1-2/ DAY NO N/A
N/A YES- 4 HOURLY YES MITROFANOFF TROPAN 4 HOURS 1-2/ DAY YES RECTUM
N/A YES- 3 HOURLY YES MITROFANOFF NO 3 HOURS 1-2/ DAY NO N/A
N/A YES- 3 HOURLY YES MITROFANOFF TROPAN 1 HOUR 7-8/ DAY YES RECTUM
N/A YES- 2 HOURLY YES MITROFANOFF NO 2 HOURS 2-3/ DAY NO N/A
GOOD COMPLIANT BLADDERYES- 3 HOURLY YES MITROFANOFF NO 3 HOURS 1 / DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA TROPAN 1.5 HOURS 5-6/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA TROPAN 2 HOURS 4-5/ DAY NO N/A
N/A NO NO N/A NO 20 MINUTES 4-5/ DAY NO NO
N/A YES- 3 HOURLY YES URETHRA NO 1 HOUR 6-7/ DAY YES RECTUM
N/A NO NO N/A NO 20 MINUTES 5-6/ DAY NO N/A
N/A NO NO N/A NO 30 MINUTES 5-6/ DAY NO N/A
N/A NO NO N/A NO 2 HOURS 4-5/ DAY NO N/A
N/A NO NO N/A NO 30 MINUTES 6-7/ DAY NO N/A
N/A NO NO N/A NO 1.5 HOURS 5-6/ DAY NO N/A
N/A NO NO N/A NO 4 HOURS 4-5/DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA NO 1.5 HOURS 7-8/ DAY NO N/A
N/A YES- 3 HOURLY YES MITROFANOFF NO 3 HOURS 3-4/ DAY NO N/A
N/A YES- TWICE DAILY NO URETHRA NO 2 HOURS 5-6/ DAY YES RECTUM
N/A YES- TWICE DAILY NO URETHRA NO 2 HOURS 5-6/ DAY NO N/A
N/A NO NO N/A NO 1 HOUR 5-6/ DAY NO N/A
N/A YES- THRICE DAILY NO URETHRA NO 1 HOUR 5-6/ DAY NO N/A
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N/A NO NO N/A NO 20 MINUTES 8-10/ DAY NO N/A
N/A NO NO N/A NO 30 MINUTES 7-8/ DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA NO 1 HOUR 7-8/DAY  NO N/A
N/A YES- TWICE A DAY NO URETHRA NO 1 HOUR 7-8/ DAY NO N/A
N/A NO NO N/A NO 3 HOURS 4-5/ DAY NO N/A
N/A NO NO N/A NO 1 HOUR 6-7/ DAY NO N/A
N/A NO NO N/A NO 1 HOUR 5-6/ DAY NO N/A
N/A NO NO N/A NO 30 MINUTES 6-8/ DAY NO N/A
N/A NO NO N/A NO 4 HOURS 4-5/ DAY NO N/A
N/A NO NO N/A NO 20 MINUTES 8-9/ DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA NO 1.5 HOURS 6-8/ DAY NO N/A
N/A NO NO N/A NO 3 HOURS 3-4/ DAY NO N/A
N/A NO NO N/A NO 30 MINUTES 7-8/ DAY NO N/A
N/A NO NO N/A NO 3 HOURS 3-4/ DAY NO NO
N/A NO NO N/A NO 2 HOURS 3-4/ DAY NO NO
N/A YES- 2 HOURLY YES URETHRA TROPAN 2 HOURS 3-4/ DAY YES RECTUM
N/A YES- 3 HOURLY YES URETHRA TROPAN 3 HOURS 3-4/ DAY YES RECTUM
N/A NO NO N/A NO 4 HOURS 1-2/ DAY NO N/A
N/A NO NO N/A NO 4 HOURS 2-3/ DAY NO N/A
N/A YES- 3 HOURLY YES URETHRA NO 30 MINUTES 6-7/ DAY YES RECTUM
N/A NO NO N/A NO 1.5 HOURS 7-8/ DAY NO N/A
N/A NO NO N/A NO 3 HOURS 3-4/ DAY NO NO
N/A NO NO N/A NO 10 MINUTES 10-12/ DAY NO N/A
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DRUGS INDEPENDENCE GARMENT CHANGE/ DAYOPERATIONS BARTHELS Q1 Q2 Q3 Q4 Q5
NO YES 3-4/DAY MMC REPAIR FROM ELSEWHERE IN APRIL 20031 1 1 1 2
NO YES 5/ DAY MMC REPAIR FROM ELSEWHERE IN JULY 20081 1 1 1 2
NO NO 3-4/ DAY COLOCYSTOPLASTY WITH MITROFANOFF AND BILATERAL REIMPLANT DONE ON 14/10/20132 0 2 2
NO NO 2/ DAY COLOCYSTOPLASTY WITH MITROFANOFF DONE ON 17/09/20131 2 0 0 1
NO YES 4-5/ DAY SURGERIES DONE FROM ELSE WHERE: MMC CLOSURE 20/07/2005;BLADDER SLING WITH MITROFANOFF 29/02/2008; 17/03/2008- ILEOCYSTOPLASTY: 18/04/2008- MITROFANOFF REVISION; 12/05/2008- SPC1 0 0 1 2
NO NO 10/ DAY NO 0 0 0 0 1
NO YES 1 / DAY MMC REPAIR -17/11/1997; COLOCYSTOPLASTY ON 20012 2 1 2 2
NO YES 1-2/DAY MMC REPAIR DONE ON 21/8/2007; CIC TRAINING ON 10/6/20122 2 1 2 2
NO YES 1/ DAY MMC REPAIR FROM ELSEWHERE ON 19/10/1997; COLOCYSTOPLASTY ON 2/10/20092 2 1 2 2
NO NO 4-5/DAY MMC REPAIR- 4/03/2008 0 0 0 0 1
NO YES 4-5/ DAY MMC  AND CUTBACK ANOPLASTY FROM ELSEWHEREIN 2004. DONE ORTHOPAEDIC PROCEDURES HERE  1 1 1 2 2
NO YES 1-2/ DAY MMC REPAIR FROM ELSEWHERE 1 2 1 1 2
NO NO 2-3/ DAY MMC REPAIR FROM  ELSEWHERE. BLADDER AUGMENTATION WITH BLADDER NECK SLING AND MITROFANOFF ON 22/04/20130 1 0 1 2
NO YES 1-2/ DAY MMC REPAIR WITH DETHETERING OF CORD FROM ELSEWHERE; VESICOSTOMY DONE ON 17/02/20102 2 1 2 2
NO YES 1-2/ DAY MMC REPAIR ON 22/06/2006 1 1 0 1 1
NO NO 2-3/ DAY MMC REPAIR FROM ELSEWHERE 4/06/20080 0 0 0 1
NO YES 1/ DAY MMC REPAIR FROM ELSEWHERE; 24/02/2012- CIC TRAINING2 2 0 1 2
NO YES 1/ DAY MMC REPIAIR FROM RANCHI ON 22/6/2006. BLADDER AUGMENT ON1 0 1 1 2
NO YES 1/ DAY MMC REPAIR- 22/06/2013 2 2 0 1 2
NO YES 1/ DAY NO 1 1 1 1 2
NO YES 1-2/ DAY MMC REPAIR IN 12/2003; CIC WITH BOWEL WASH TRAINING IN 21/4/2006 AND MITROFANOFF IN 1/7/2013; AUGMENT WITH BLADDER NECK SLING0 0 0 1 2
NO NO 2-3/ DAY MMC REPAIR ON 10/11/2003. CIC TRAINING ON  24/11/20051 1 1 2 2
NO YES 1-2/ DAY MMC REPAIR ON 21/5/2007 0 0 1 0 2
NO YES 1/ DAY MMC REPAIR FROM ELSEWHERE IN 12/1996; CIC TRAINING IN 9/2/20042 1 1 2 2
NO YES 1/ DAY MMC REPAIR IN MAY 2005; COLOCYSTOPLASTY WITH APPENDICULARE MITROFANOFF 4/7/20072 2 1 1 2
NO YES 1/ DAY MMC REPAIR FROM ELSEWHERE IN 10/2005. R-L TUU WITH MITROFANOFF ON 14/11/12. ILEOCYSTOPLASTY ON 2/1/13. LAP CHOLECYSTECTOMY ON 28/2/20142 1 1 1 2
NO NO 2-3/ DAY MMC REPAIR ON 4/3/2004; CIC AND ENEMA TRAINING 8/3/2011; AUGMENT WITH BLADDER SLING AND MONTI ON 8/3/2011;  BLADDER NECK DIVISION  ON 7/9/2011; SCOPY WITH BLADDER NECK DIVISION AND MONTI  ON 5/5/2013 0 0 0 0 1
NO NO 2-3/ DAY MMC REPAIR ON 29/10/2006; VP SHUNT ON 6/2009; ILEOCYSTOPLASTY WITH MITROFANOFF AND REIMPLANT ON 12/12/20111 1 1 1 2
NO NO 1/ DAY AUGMENTATION OF THE BLADDER WITH MITROFANOFF DONE ON 20002 1 1 2 2
NO NO 2-3/ DAY MMC REPAIR ON 23/8/2009; CIC TRAINING WITH BOWEL WASH ON 19/8/2013
NO NO 4-5/DAY MMC REPAIR ON 2/4/2011; CIC TRAINING ON 22/10/2011
NO NO 4-5/ DAY MMC REPAIR ON 12/10/2011
NO NO 2-3/ DAY MMC REPAIR ON 25/6/2013
NO NO 5-6/DAY MMC REPAIR ON 29/10/2013
NO NO 4-5/DAY MMC REPAIR ON 10/9/2013
NO NO 3-4/ DAY MMC REPAIR ON 14/8/2013
NO NO 5-6/ DAY MMC REPAIR ON 11/9/2013
NO NO 3-4/ DAY MMC REPAIR DONE ON 10/12/2013
NO NO 4-5/ DAY MC REPAIR ON 25/11/2012
NO NO 3-4/DAY MMC REPAIR ON 25/11/2012; CIC TRAINING GIVEN
NO NO 2-3/DAY MMC REPAIR IN JULY 2010 FROM ELSEWHERE; HAD ENDOSCOPIC 3RD VENTRICULOSTOMY 3 MONTHS LATER; BLADDER AUGMENT
NO NO 1-2/ DAY MMC REPAIR DONE ON 25/08/2011, ORCHIDOPEXY LEFT AND CIRCUMCISION ON 27/3/2013
NO NO 5-6/ DAY MMC REPAIR DONE ON 14/09/2013
NO NO 5-6/ DAY MMC REPAIR DONE ON 25/9/2013
NO NO 5-6/ DAY MMC REPAIR DONE ON 26/10/2014
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NO NO 5-6/DAY MMC REPAIR DONE ON 23/7/2013
NO NO 5-6/ DAY MMC REPAIR DONE ON 5/9/2013
NO NO 4-5/ DAY MMC REPAIR DONE ON 14/8/2013
NO NO 5-6/ DAY MMC REPAIR DONE ON 16/8/2013
NO NO 4-5/ DAY MC REPAIR DONE ON 5/8/2013
NO NO 5-6/ DAY MMC REPAIR DONE ON 14/8/2013
NO NO 5-6/ DAY LMC REPAIR DONE ON 31/01/2013
NO NO 4-5/ DAY MMC REPAIR DOEN ON 26/6/2013
NO NO 3-4/ DAY MC REPAIR DONE ON 21/4/2012
NO NO 2-3/ DAY MMC REPAIR DONE ON31/5/2012; TRIED CIC  TRAINING ON 14/12/2013- OPENING STENOTIC
NO NO 3-4/ DAY MMC REPAIR DONE ON9/8/2012; VP SHUNT ON 30/4/2013
NO NO 2-3/ DAY MMC REPAIR DONE ON 16/11/2010
NO NO 3-4/ DAY MMC REPAIR DONE ON 31/10/2012
NO NO 3-4/ DAY MMC REPAIR DONE ON 19/11/2012 
NO NO 3-4/ DAY MMC REPAIR DONE ON22/11/2012
NO NO 1-2/ DAY MMC REPAIR DONE ON 23/2/2012; CIC TRAINING 21/9/2013
NO NO 1-2/ DAY MMC REPAIR DONE ON 
NO NO 1-2/ DAY MC REPAIR DONE  ON 30/8/2010
NO NO 1-2/ DAY MMC REPAIR DONE ON 30/11/2011
NO NO 3-4/ DAY MMC REPIR DONE ON 16/4/2011
NO NO 2-3/ DAY MMC REPAIR DONE ON 11/7/2011
NO NO 2-3/ DAY MMC REPAIR DONE ON 21/4/2011
NO NO 2-3/ DAY BILATERAL END URETEROSTOMY DONE FOR CRF ON 8/6/2012
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Q6 Q7 Q8 Q9 Q10 PIN-Q; Q1 Q2 Q3 Q4
3 3 2 2 1 4 2 1 3
3 3 2 2 1 2 2 1 3
3 3 2 2 1 2 2 4 0
1 1 0 0 0 0 2 0 0
2 3 2 1 1 1 0 1 2
0 1 0 0 0 4 2 3 4
3 3 2 2 1 1 0 0 1
3 3 2 2 1 1 0 0 0
3 3 2 2 1 0 0 0 3
1 1 0 0 0 2 0 4 1
3 3 2 2 1 3 0 3 0
3 3 2 2 1 3 0 3 1
2 2 1 1 1 3 0 4 0
3 2 2 2 1 1 1 2 0
2 1 0 0 0 4 2 1 2
2 1 0 0 0 4 0 4 4
3 3 2 2 1 2 0 1 2
2 2 2 0 0 1 0 3 4
1 2 1 1 0 0 2 0 0
3 3 2 2 1 4 4 0 0
3 3 1 1 1 1 0 3 0
3 3 2 2 1 3 0 2 3
3 3 1 2 1 4 2 3 4
3 3 2 2 1 2 0 2 1
3 3 2 2 1 1 0 0 1
3 3 2 2 1 4 0 0 0
2 3 1 1 0 2 0 4 3
3 3 2 2 1 0 2 4 0
3 3 2 2 1 2 0 2 4
MMC REPAIR IN JULY 2010 FROM ELSEWHERE; HAD ENDOSCOPIC 3RD VENTRICULOSTOMY 3 MONTHS LATER; BLADDER AUGMENT WITH MITROFANOFF, BILATERAL URETERIC REIMPLANT AND BLADDER NECK TIGHTENING DONE ON 13/2/2013
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Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13
3 3 2 0 3 2 0 4 1
4 4 3 2 3 3 1 2 3
4 4 4 4 4 4 0 4 4
0 0 0 0 4 0 0 2 0
4 2 1 2 0 0 0 0 2
4 3 2 0 3 0 1 1 3
4 4 0 4 1 0 0 1 0
3 4 1 3 2 1 0 0 0
2 2 0 0 1 0 0 2 0
4 4 4 4 2 2 2 3 4
4 4 4 0 1 3 0 3 3
4 4 4 4 2 3 2 3 3
4 4 4 0 4 4 4 2 4
2 2 0 0 0 2 2 2 1
4 2 2 4 2 2 2 2 4
4 4 4 0 4 4 0 4 4
1 1 2 0 2 0 2 2 0
2 3 2 1 3 2 1 1 3
0 1 0 0 0 0 0 0 0
0 0 2 2 0 2 1 2 2
2 4 3 2 4 0 0 0 1
4 2 0 2 3 1 2 2 2
4 2 4 3 3 2 3 4 4
4 4 4 1 4 4 1 3 4
4 4 0 3 1 1 0 0 0
4 4 4 0 4 4 2 4 4
4 4 4 4 3 1 4 2 4
4 4 2 2 0 0 0 2 2
4 3 4 4 2 4 2 4 4
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Q14 Q15 Q16 Q17 Q18 Q19 Q20 VISUAL ANALOGUE SCALE
2 2 4 3 4 3 0 80%
2 2 1 2 1 3 2 90%
2 4 0 4 0 4 4 50%
0 0 2 0 0 2 0 80%
0 1 0 0 0 0 0 60%
3 0 0 4 4 2 2 20%
0 4 1 3 4 2 2 85%
0 3 1 3 4 2 2 70%
0 2 2 4 1 0 0 90%
3 3 3 3 2 2 3 50%
3 4 4 4 3 3 3 70%
3 2 3 4 4 4 3 60%
3 3 3 4 4 4 3 50%
3 3 1 2 2 2 2 70%
4 3 1 2 3 2 3 50%
4 4 0 4 4 4 4 20%
0 2 0 0 0 0 0 90%
2 3 1 3 3 2 2 60%
0 0 0 0 0 0 0 75%
2 2 2 1 1 0 3 90%
2 3 0 3 4 2 1 40%
3 1 3 3 2 2 3 90%
3 4 3 4 3 4 4 10%
1 4 3 2 2 4 2 70%
0 4 1 3 4 2 2 80%
4 4 4 4 4 0 4 50%
3 4 3 1 4 4 3 20%
2 1 2 2 0 1 2 70%
4 1 2 2 2 4 2 90%
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